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Abstract
This is a review of hypnotic drug risks and benefits. Almost every month, new
information appears about the risks of hypnotics (sleeping pills). The most
important risks of hypnotics include excess mortality (especially overdose
deaths, quiet deaths at night, and suicides), infections, cancer, depression,
automobile crashes, falls, other accidents, and hypnotic-withdrawal insomnia.
Short-term use of one-two prescriptions is associated with even greater risk per
dose than long-term use. Hypnotics have usually been prescribed without
approved indication, most often with specific contraindications, but even when
indicated, there is little or no benefit. The recommended doses objectively
increase sleep little if at all, daytime performance is often made worse (not
better) and the lack of general health benefits is commonly misrepresented in
advertising. Treatments such as the cognitive behavioral treatment of insomnia
and bright light treatment of circadian rhythm disorders offer safer and more
effective alternative approaches to insomnia.
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Introduction
This is the third update and expansion of scientific review pre-
sented October 26, 2015 to the Commissioner of the Food and 
Drug Administration (United States FDA) as part B of Petition 
FDA-2015-P-3959.  That petition is accessible at http://www.
regulations.gov/#!docketDetail;D=FDA-2015-P-3959 along with 
peer Comments responding to that Petition. Almost every month, 
new information about the risks of hypnotics (sleeping pills) 
appears.
Risks of hypnotic drugs
Hypnotic drugs increase all-cause mortality
Use of hypnotic drugs is associated prospectively with a greatly 
increased risk of all-cause mortality. Some of this mortality has 
been documented as deaths caused by hypnotics by Medical 
Examiners, attributed to respiratory arrests resulting from 
“overdose.” However, it is likely that many deaths from respira-
tory depression occur among patients never examined by coro-
ners, especially when the death is caused by a combination of 
hypnotics with other contributing factors, so that the lethal hyp-
notic dosage may by itself have been within currently-customary 
dosage ranges. In addition to respiratory depression, hypnot-
ics are related to serious illnesses and premature deaths from 
cancer, serious infections, mood disorders, accidental injuries, 
suicides and homicides.
The overdose epidemic
Only a small fraction of U.S. deaths has been medically 
evaluated by coroners and Medical Examiners. Thus, it is 
commonly assumed that overdose deaths have been grossly 
under-reported. Despite such underestimation, U.S. drug and 
opioid overdose deaths reported in 2014 reached 47,055, a 137% 
increase since 20001, and rapidly increased to 72,000 per year in 
2017–20182. Self-injury deaths including overdoses that might 
have been accidental or cause-undetermined are higher3, so total 
self-injury deaths would be estimated well above 72,000 for 
2018. U.S. use of hypnotics dramatically increased over most of 
the same interval until about 20124 but then have subsequently 
decreased5. 
Available death certificate reports seem unclear, but perhaps 
one third of death certificates listing overdose with an opioid 
as a cause of death also lists a benzodiazepine, Z hypnotic, or 
barbiturate as a cause of death (retrieved from CDC Wonder). 
Such death certificate data are known to underestimate drug 
involvement, due to insufficient assays done and insensitivity of 
assays when blood is not frozen soon after death.  In about half 
of overdose reports, the drug causing death has been unspecified6. 
A very recent study combining Medical Examiner toxicity 
reports with prescription records suggested that 76% of over-
dose patients had a benzodiazepine agonist prescription: e.g., one 
quarter of the patients had a prescription for the hypnotic 
zolpidem7. Some older studies are consistent with these high 
estimates of combination overdoses8. An opioid prescription is 
more likely to lead to overdose when a hypnotic is also prescribed9. 
Indeed, among women who had received an opioid prescrip-
tion, the added overdose risk of taking high-dose benzodiazepine 
or zolpidem was comparable to the risk of high-dose opioid10. It 
appears that some of the hazard associated with zolpidem was 
attenuated when confounding depression was included in the 
statistical adjustment; however, since hypnotics cause depression 
(see below), hypnotics would seem indirectly causal for much of 
the depression-related excess hazard10,11. There have also been 
several thousand yearly reported overdoses involving a hyp-
notic in which an opioid was not involved. With both opioid and 
other-drug poisoning increasing12, so great is the recent increase 
in overdose and suicide deaths that they have lowered overall life 
expectancy in much of the U.S. adult population13,14. Overdoses 
kill more Americans than automobile accidents or murders. On 
August 31, 2016, the FDA announced “boxed warnings” about 
the lethality of combinations of opiates and benzodiazepine 
agonists including benzodiazepine  hypnotics. 
Aside from overdose deaths, benzodiazepines were involved in 
a comparably increasing number of emergency room visits over 
a similar time interval, and over half of these also involved opio-
ids, alcohol, or all three in combination15. Combined overdoses of 
opiates and benzodiazepine agonists had more severe out-
comes. Suicides from all causes per capita have been increasing, 
particularly among women, and overdoses from unspecified 
drugs have been increasing, particularly since 2007, at which 
time generic zolpidem became available, increasing zolpidem 
prescribing16. Hypnotics may increase suicide by increasing 
depression, impairing judgement, and creating behavioral confu-
sion (see below), as well as through pharmacologic overdosage.
There is some evidence that increasing hypnotic use is 
epidemiologically associated with the social despair and under-
employment similar to that associated with the increasing opioid 
overdose epidemic. This despair is linked to depressed mood, 
sleep complaints, weakness, and poor motor coordination17.
Forty-six epidemiologic studies of mortality
Of 46 epidemiologic studies that provided comparable risk ratios 
for mortality associated with hypnotics, 43 found that hypnotics 
      Updates from Version 2
This update adds new findings about the accelerating overdose 
epidemic that is suddenly reducing U.S. life expectancy. The 
overdose role of hypnotics and other benzodiazepine agonists 
in combination with opioids is further reviewed.  Evidence is 
expanded that most hypnotic prescriptions are not indicated—
indeed, the great majority have been contraindicated or result 
in misuse.  The “weak” evidence relating minimal benefit with 
indicated hypnotics does not support over 90% of actual U.S. 
ingestion, wherein the hypnotic was not indicated or rather 
was contraindicated.  For >90% of cases, there seems to have 
been no scientific evidence of benefit.  On the other hand, 
the evidence of severe risks appears to apply to all hypnotic 
utilization whether or not given for an approved indication.  
Evolving concern with hypnotic risks provides many new studies 
for this review, including four additional large epidemiologic 
analyses relating hypnotic prescriptions to excess mortality and 
two complementary meta-analyses demonstrating associations of 
hypnotic prescriptions to specific cancers.  Meanwhile, the data 
base has grown demonstrating superior results with cognitive-
behavioral therapy of insomnia and with bright light treatment.
See referee reports
UPDATE
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were associated with excess mortality, as listed in Appendix A. 
In addition, a 44th study of stroke patients showed elevated 
mortality among those receiving hypnotics and various other 
psychotropic drugs18. One exception was an early small study by 
Merlo et al. that nevertheless found hypnotics associated with 
cancer deaths19. Another partial exception was a study from 
Taiwan that found benzodiazepine hypnotics associated with 
significant excess mortality, but found zolpidem 10 mg associated 
with significantly reduced mortality in adjusted models, despite 
a significantly-increased unadjusted mortality risk for zolpidem 
and a significantly-increased adjusted risk of cancer mortality 
for zolpidem20. In a comment to this report appearing with it 
on the internet, I have questioned the statistical methods of 
adjusting zolpidem risks20. A large study of benzodiazepine use 
and mortality was not included because it was not focused on 
hypnotics, specifically excluded nonbenzodiazepine “Z” drugs 
such as zolpidem, and failed to compare drug use of cases and 
controls during follow-ups21.
Only that one of the 46 epidemiologic studies of hypnotic drugs 
reported any association with improved patient survival, and that 
one only by relying on questionable statistical adjustments20. 
None of the other 45 studies found hypnotic drug risk ratios 
significantly less than 1.0. That is, in 45 studies there was no 
evidence that hypnotics ever benefit patient survival. To find 
44 of 46 studies showing a positive risk ratio was very highly 
significant, P<0.000001. Also, the evidence of association satis-
fied all nine Bradford Hill criteria for inferring causality22, though 
skepticism despite meeting these criteria may be warranted23. 
There remain questions concerning the magnitude of the 
causality. The randomized placebo-controlled trials I have sug-
gested would help clarify the magnitude of hypnotic health 
impairment22.
Of the 46 epidemiologic studies, 35 individual studies reported 
statistically significant mortality odds ratios, risk ratios, or haz-
ard ratios for hypnotics exceeding 1.0. All 22 studies reporting 
on samples of >14,000 people found significant mortality risks, 
but nine of 22 smaller studies found positive trends that were not 
significant. Most of the non-significant reports were among the 
earliest 15 published before 2006. Of studies analyzing follow- 
ups of 8 years or less, 23 of 27 studies reported a significant 
association, but of studies with longer follow-ups, only 13 of 
17 studies observed significant mortality risks. This may 
suggest that during long prospective follow-ups, many patients 
initially taking hypnotics will discontinue hypnotic usage, whereas 
many controls not using hypnotics at prospective baseline may 
have begun using hypnotics during a long follow-up, so that the 
longer the follow-up, the more mixing of hypnotic-consuming 
and control groups becomes likely. Mixing weakens the risk-
ratio contrasts observed. In long follow-ups, one is also studying 
the selected survivors of the more marked short-term risks that 
have been recently described24,25.
Most of the 46 studies reported mortality risk ratios of less than 
1.5, but some of the highest quality studies reported among the 
highest risk ratios. Four large studies were particularly persuasive, 
as presented below.
The Geisinger Health System study
From electronic records of the Geisinger Health System in East-
ern Pennsylvania, a sample of 34,205 patients was drawn with 
carefully controlled 1:2 matching of hypnotic users with non-user 
controls for age, gender, smoking, and various comorbidities. 
Compared to a reference hazard ratio of 1.0 for non-users of hyp-
notics, the fully-adjusted mortality hazard ratio for use of 0.4–18 
hypnotic doses per year was 3.60 (2.92–4.44, 95% CI), for those 
using 18–132 doses per year, the hazard ratio was 4.43 (3.67–
5.36), and for >132 doses per year, the hazard ratio was 5.32 
(4.50–6.30)26. Each of these associations was significant with 
P<0.001. Sensitivity studies showed that little of the hypnotic- 
associated mortality could be explained by known confounders 
or use of hypnotics before commencement of the study. In this 
sample, prescriptions for each of the following drugs were found 
to significantly predict increased mortality with statistical signifi-
cance: zolpidem, temazepam, eszopiclone, zaleplon, triazolam, 
flurazepam or quazepam, and barbiturates prescribed to induce 
sleep. This review is principally concerned with these popular 
hypnotics for which drug-specific mortality data are avail-
able. Barbiturates prescribed at night for sleep considered 
as a group had about the same empirical hazard ratios as the 
benzodiazepines and zolpidem, but the observed hazard ratio 
for eszopiclone was significantly higher than that of barbitu-
rates, possibly biased by the shorter average follow-up intervals 
for this more-recently introduced drug26.
The Weich et al. study
In a sample of over 100,000 hypnotic users and matched con-
trols from the representative British General Practice Research 
Database27, users of 1–30 defined daily doses (DDD) of hypnot-
ics and anxiolytics within a year had fully adjusted dose-respon-
sive mortality hazard ratios of 2.55 (2.42–2.69, 95% CI) for 1–30 
DDD (defined daily doses in the first year); 3.78 (3.54–4.04) 
for 31–60 DDD, 4.19 (3.84–4.58) for DDD 61–90, and 4.51 
(4.22–4.82) for DDD >90. Extensive full adjustment for poten-
tial confounders resulted in only very small and inconsistent 
decreases in the estimated hazard ratios, and many methodological 
details were focused on minimizing possibilities of confound-
ing. Use of benzodiazepine hypnotics alone was associated with 
higher hazard ratios than use of “Z” hypnotics alone. These 
hazard ratios were remarkably similar to those from the 
Geisinger Health System, considering the many differences in 
drug characteristics, samples, design, confounder controls, and 
analyses. Note that as in the Geisinger Health System study, 
much of the mortality was associated with early deaths after 
limited doses of hypnotics, perhaps as little as one-two prescrip-
tions filled or refilled.
Norwegian Pharmacy Database
A representative study of the Norwegian Pharmacy Database 
found that benzodiazepine-receptor-agonist use was associated 
with a mortality odds ratio of 2.30 (2.20–2.40)28. The authors 
argued that terminal illness caused an upturn in benzodiazepine-
receptor agonist use shortly before death (which might be 
appropriate for hospice care), and therefore they argued that the 
increased benzodiazepine-agonist use among those who would 
die was demonstrated as a confound of terminal illness. To the 
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contrary, their data demonstrated an excess of benzodiazepine use 
even among those who would not die until 22 months or later, so 
the benzodiazepine use of this population was elevated before 
the terminal upturn in hypnotic usage that the authors had dem-
onstrated. Also, the upturn in death-associated hypnotic use 
6–10 months before subsequent death might be consistent with 
a causal lethal hazard resulting from only a few short months’ 
exposures to hypnotics. The Norwegian Pharmacy Database did 
not enable this study to identify terminal illnesses, to analyze 
comorbidities or to control for other confounders.
The Palmaro et al. study
In this large study, both French and British case-control samples 
were drawn from reasonably-representative national samples24. 
Results had many similarities to those of Weich et al.27 despite 
numerous differences in statistical design. Substantially lower 
overall hazard ratios were found in the French sample (not all 
significant after adjustment), perhaps because a large number 
of occasional users were included. An important finding was the 
much higher hazard ratios associated with the initial 3–6 months 
of hypnotics-benzodiazepines use, as high as 11.12 (95% 
CI, 9.91–12.47) for the 3-month analysis of the British sample. 
This sharpened the evidence, also noted in the three previous 
studies discussed, that although dose-response is observed over 
several years, much of the hypnotic-associated hazard is observed 
during the early months of usage after as little as one or two 
prescriptions.
It should be noted that Weich et al.27 and Palmaro et al.24 found 
significant hazard ratios associated with diazepam and other 
benzodiazepines that are not considered hypnotics (though 
tranquilizer benzodiazepines may often be used for sleep). These 
more modern data with better drug identification and measure-
ments of prescriptions during follow-up must be considered more 
reliable, but neither “Valium” nor “Librium” had been associated 
with excess mortality in the previous large U.S. CPSII study29. 
One might argue that if diazepam has a different hazard from 
temazepam, for example, this specificity tends to bolster the 
evidence for causality with temazepam30. On the other hand, it 
would not be clear if the specificity is in the drug’s pharmaceu-
tical effects, in its absorption and half-life, in its usual time of 
administration, in other aspects of frequency and dosage of 
administration, or in various associated confounders.
These epidemiologic studies had many limitations22. However, 
the limitations that would tend to bias the results towards under-
estimating the associations of hypnotics and mortality appeared 
more influential than those that would bias towards overestima-
tion of the risks. In particular, studies with the most careful efforts 
to control for confounders found that such control made little 
difference in the estimated risk ratios, but the hazard ratios 
in these carefully-controlled studies tended to be higher. The 
risk ratios derived, like the studies themselves, were extremely 
heterogeneous, probably due to differences in the size, age, 
gender, and ethnicity of samples and their health status, the 
nature of the hypnotics studied, the accuracy with which the 
drugs examined and their dosages were known, the control 
variables available, and the duration of follow-up observations to 
ascertain mortality. Meta-analyses attempting to group 40 such 
heterogeneous studies would not be clarifying.
Short-term hypnotic use is unsafe
Data provided by Palmaro et al.24 and Chung et al.25 expanded 
the hints in the other large epidemiologic studies10,26–28 that short-
term hypnotic usage has surprisingly high risks: apparently 
short-term hypnotic use has higher risks than long-term usage on 
a per dose or per-unit-time basis. It is logical that for a patient 
with an “overdose” of common contributory factors such as aging, 
obesity, sleep apnea, alcohol overuse, and opiate use, even a 
single hypnotic dose could be lethal on the first night of con-
sumption. Depending on the drug and the patient’s metabolic 
capacity, the hypnotic drug concentration in blood could increase 
for the first few consecutive nights of dosage, but eventually, 
developing tolerance might make each dose less risky among 
those who had survived the initial doses. There would continue 
to be deaths at a lower rate after tolerance develops because of 
hypnotic dose-escalation in response to tolerance, addition of 
other sedatives or opiates, especially-heavy pre-sleep alcohol 
consumption, body position, altitude, upper respiratory infections, 
and other contributing factors that could suddenly produce 
hypnotic lethality even after several years of steady consumption. 
In addition, new consumption of non-sedative drugs that impair 
liver drug metabolism and even foods such as grapefruit can 
suddenly make a patient more vulnerable to a customary dose. 
Understanding these considerations, limitation of hypnotic pre-
scribing to a small number of doses or a single prescription 
cannot be considered safe.
Are insomnia and depression explanatory confounders?
Several reports carefully examined insomnia and depression as 
potential confounders of the association of hypnotics with mortal-
ity, finding that insomnia and depression could explain little if any 
of this association27,31–33. Note also that the evidence does not per-
mit us to assume that causality between insomnia, depression, and 
hypnotic usage is a one-way path when contemplating confounder 
control, as there is reverse causality34,35.
Summary of mortality risk epidemiology
Altogether, the epidemiologic literature is conclusive that hypnotic 
use is associated with excess mortality. The better studies tend to 
show very high dose-response risk ratios suggesting association 
with a very large number of deaths. A supplement to the Geisinger 
Health System data showed that the risk ratios demonstrated lead 
to estimated U.S. deaths associated with hypnotic usage of the 
same order of magnitude as those associated with cigarette use, 
around 300,000–500,000 per year26. Evidence has been presented 
from several independent studies that most of these deaths cannot 
be attributed to known forms of confounding, and indeed, adjust-
ment for the major confounders such as smoking and comorbidi-
ties produced little change in the estimated associations in most of 
these studies. Authors acknowledge that their estimates of adjusted 
association of hypnotics and mortality could be influenced by 
inadequate ascertainment of confounding factors or lack of con-
trol for a very large number of potential confounds with small or 
rare effects. It is because skeptics may question whether the strong 
associations of hypnotics with mortality are causal, despite data 
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fulfilling the Bradford Hill criteria for inferring causality23, that 
large post-marketing controlled trials of vulnerable patients may 
still be needed22.
Hypnotic drugs have a long history of delayed recognition 
of mortality risks
Despite its well-known risks of lethality, pentobarbital was nev-
ertheless for decades a preferred hypnotic routinely prescribed 
for patients seeking sleep aids. In the U.S., today, the most nota-
ble human application of pentobarbital is in implementing the 
death sentence. Although it has been believed that the more 
modern benzodiazepine and benzodiazepine-receptor-agonist 
hypnotics that replaced barbiturates have higher acute mar-
gins of safety and therefore lower risks than pentobarbital, death 
certificate and epidemiologic data do not confirm that the newer 
drugs are significantly safer than barbiturates in routine use22,36.
Hypnotics produce an excess of deaths at night
In the first Cancer Prevention Study, the percentage of deaths 
at night were found to be increased by 15.6% among those 
taking hypnotics (P=0.01), presumably due to respiratory sup-
pression37. In that study, the higher percentage of excess deaths 
at night associated with taking hypnotics accounted for about one 
third of total excess mortality associated with hypnotics. These 
nocturnal deaths were attributed to other causes, even though 
quiet respiratory suppression as a cause would explain the higher 
percentage of nocturnal deaths observed among those taking 
hypnotics than among controls.
The mechanisms of dangerous hypnotic respiratory depression 
are well-understood. The common hypnotics including barbitu-
rates, benzodiazepines, the “Z” drugs and other benzodiazepine- 
receptor agonists bind to gamma-aminobutyric acid (GABA) 
receptors. These ligands-agonists alter the configuration of 
the receptors to allow negative chloride ions to more readily 
enter the neurons, where the chloride negatively hyperpolar-
izes the membranes and inhibits the neurons from firing. When 
they depress neural respiratory center firing, such drugs can 
acutely suppress respiration and in large enough dosage, or when 
individuals are particularly sensitive, may effectively arrest 
respiration, which leads rapidly to cardiac arrest and consequent 
death36,38,39. Respiratory depression is accordingly, and accu-
rately, listed among zolpidem’s warnings and precautions40. The 
barbiturates and alcohol bind to different locations on GABA 
receptors, where they exert additive or perhaps synergistic res-
piratory depression effects which may add to benzodiazepine- 
agonist effects41. An antihistamine, diphenhydramine, also binds 
to GABAA receptors, but it does not seem known whether the 
actions of diphenhydramine on GABA receptors are similar to 
benzodiazepines. Opiates bind to mu (μ) opioid receptors on res-
piratory neurons, where they hyperpolarize neural membranes by 
opening potassium channels42. Thus opiates, benzodiazepine ago-
nists, and alcohol have additive or synergistic effects inhibiting 
respiratory neurons41. Hypnotics inhibiting respiration would be 
expected to produce quiet deaths at night.
Hypnotics can cause serious and potentially lethal 
infections
A meta-analysis of available placebo-controlled randomized 
clinical trials showed that hypnotics cause infections 
(p<0.00001)43. Because these clinical trials randomized hypnot-
ics versus placebos, the 44% higher infection rate among par-
ticipants who were given hypnotics was proven to be caused by 
the hypnotics. Moreover, the lead manufacturer of zolpidem has 
acknowledged that zolpidem induces infections, based on that 
manufacturer’s own clinical trials data44. The FDA also found 
dozens of reports of zolpidem-related severe infections among 
post-marketing reports40.
Extensive epidemiologic data demonstrated that hypnotics are 
associated with increased pneumonia including fatal pneumonia45. 
Likewise, triazolam was associated with pneumonia in Japan, per-
haps attributable to increased aspiration46. This finding was not 
confirmed by one Taiwanese study47, but another Taiwanese study 
focusing on patients with sleep disturbances found that use of 
zolpidem was associated with 62%–91% increased hospitalizations 
for serious infections48. A Taiwan study of patients with chronic 
obstructive pulmonary disease found highly significant odds ratios 
associated with benzodiazepine use of 9.3 for pneumonia, 10.4 for 
acute chronic obstructive pulmonary disease (COPD) exacerba-
tion, 45.0 for acute respiratory failure, and 18.6 for cardiopulmo-
nary arrest; whereas the odds ratios for “Z” drugs such as zolpidem 
were of almost similar magnitude 325. In confirmation, note in the 
Geisinger Health Study supplement, Table 726, mortality haz-
ard ratios were likewise specifically elevated among hypnotics 
users with COPD. Other Taiwanese studies observed that use of 
zolpidem was associated with increased risk of pyogenic liver 
abscess49, pancreatitis50, and pyelonephritis51, and zopiclone 
with pancreatitis and other conditions52. British data showed that 
use of benzodiazepines and use of the hypnotic zopiclone (con-
taining 50% eszopiclone as the active ingredient) were signifi-
cantly related to asthma exacerbation and to all-cause mortality 
following exacerbation53. This asthma study described some of 
the benzodiazepine-agonist-mediated impairments of immune 
surveillance53. Perhaps as a consequence of post-hospital 
continuation of benzodiazepines and resultant infection, use of 
benzodiazepines was associated with 23% increased hospital 
readmission in North Carolina54. In summary, epidemiologic 
evidence indicates that hypnotics not only cause the mild upper- 
respiratory infections most commonly reported in available 
controlled clinical trials43, but also more severe and life- 
threatening infections. Since such infections demonstrably impair 
survival, infection is shown to be an additional mechanism 
by which hypnotics covertly increase mortality. The death 
certificate would be likely to list the infection as a cause of 
death but not the hypnotic which may have caused that infection.
Animal studies confirm that hypnotics can cause infections. A 
controlled trial demonstrated in mice that diazepam exacerbated 
Streptococcus pneumoniae infection through GABAA receptors, 
partly explaining the underlying immune mechanisms55. In mice, 
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diazepam also exacerbated cowpox, a viral infection56. Midazolam 
impaired equine immune responses, attributable to effects on mac-
rophage peripheral benzodiazepine receptors (now called TSPO)57. 
Evidence for involvement of the peripheral benzodiazepine 
receptor TSPO in immune impairment also came from specific 
test compounds in mice58. Thus, hypnotic drugs cause increased 
risk of potentially lethal infections in controlled laboratory 
experiments.
Hypnotics are associated with increased cancer
Human clinical trials strongly suggested that hypnotics 
cause cancer
A compilation of randomized controlled trials of hypnotics showed 
12 cancers or tumors of uncertain malignancy reported among 
participants randomized to a hypnotic, but none (zero) among 
those randomized to placebo (P=0.032, two-tailed Fisher Exact 
Test)59. When the FDA repeated this audit of their controlled trials 
data, they counted 13 cancers among those randomized to 
hypnotics versus none (zero) from placebo59.
The controlled-trials compilations described above did not include 
indiplon, an unlicensed zaleplon-like benzodiazepine agonist and 
hypnotic, for which studies published subsequently indicated three 
incident cancers in the indiplon groups and none in the randomized 
control groups60,61. The compilations did include cancers associ-
ated with the marketed hypnotic ramelteon that admittedly has a 
very different molecular mode of action from the benzodiazepine 
agonists.
The FDA was not persuaded that these human controlled-trials 
data required regulatory action, because most of the definite can-
cers were only minor skin cancers, because of heterogeneities 
in the data, and because the cancers were recognized after such 
short randomization periods. Nevertheless, the controlled trials 
data suggested more than skin cancer. There were cancers of 
organs apart from skin noted among those treated with hypnotics 
but none among those randomized to placebo. Reconsideration 
of FDA’s deferral of action is now encouraged by new animal 
testing and new epidemiologic findings: over half of the research 
referenced in this manuscript appeared after that FDA deferral 
of action.
Because hypnotics seem to cause cancers to be suddenly 
recognized during short clinical trials, e.g., from one month to 
one year, the short-term effects are likely to arise more from 
hypnotics promoting progression of tiny pre-existing cancers 
rather than from effects upon microscopic cancer initiation. Such 
progression may cause a cancer death, whether or not the 
hypnotics initiated the cancer.
Animal studies proved that hypnotics cause cancer
The animal data in the FDA files for zolpidem indicated that 
increasing doses of zolpidem fed to rats resulted in increasing 
numbers of renal liposarcomas and lipomas combined (statis-
tically significant). These data also showed increased thyroid 
follicular adenomas and carcinomas combined, and increased 
testicular interstitial cell adenomas, but the latter findings did not 
reach statistical significance62. There were no such tumors – that is, 
zero tumors – in the placebo groups. These studies were too small, 
however, to have substantial power for these neoplasms. Expert 
FDA pharmacy examiners interpreted the data as suggesting an 
unknown degree of cancer risk for humans.
These experiments, which showed tumors resulting from feed-
ing zolpidem to rats and suggested a dose-dependent relationship, 
apparently were never extended, clarified, published, or otherwise 
followed up.
Similarly, the animal data used for eszopiclone evaluation relied 
largely on old zopiclone data, since eszopiclone is roughly 
50% of zopiclone, and eszopiclone is thought to be the active 
isomer. Along with other issues, the animal evidence that zopi-
clone caused animal cancers was of great enough concern to 
FDA’s scientists, that at least five FDA scientists and medical 
officers recommended against approval of eszopiclone63. Tumors 
of the lung in rodents were of special concern; these findings also 
anticipated the human-specific association of hypnotics with lung 
and esophageal cancers, as will be described below. Despite the 
cancer evidence and the recommendations of its own experts, 
the FDA nevertheless approved eszopiclone as a hypnotic.
Since zolpidem and eszopiclone were evaluated, much additional 
evidence has appeared relating hypnotics to cancer. Amerio et al. 
systematically surveyed FDA records including much animal data 
not included in the earlier compilation of hypnotics trials and con-
cluded that hypnotics and sedatives had among the most elevated 
cancer hazards among psychotropic drugs64.
In vitro studies strongly suggest that hypnotics cause 
cancer
Hypnotics can damage chromosomes. Zopiclone, zaleplon, 
and ramelteon are clastogenic63,65,66. Clastogens are potentially 
mutagenic agents that induce disruption or breakages of chro-
mosomes. This process can lead to carcinogenesis. Cells that are 
not killed by the clastogenic effect may become transformed to 
cancer67. One of the several formulations of zolpidem was said 
from in vitro studies not to be clastogenic68. Other than the four 
drugs mentioned, no information has been located that other 
hypnotic drugs found to be associated with cancer have ever 
been adequately tested for clastogenicity. Clastogenicity is 
one mechanism by which hypnotics are likely to be carcino-
genic, through either initiating cancers or promoting progression 
through additional mutations of cancer cells, or both.
The alterations of immune surveillance produced by benzodi-
azepine agonists, discussed in relation to infection above, suggest 
additional mechanisms by which cancer initiation and progression 
might be facilitated or disinhibited69. Hypnotic-initiated increases 
in infections and consequent inflammation is another potential 
carcinogenic mechanism. These animal-demonstrated and in-vitro 
mechanisms for carcinogenicity of hypnotics, that have been widely 
ignored, support evidence that hypnotics cause human cancer.
Human epidemiology studies demonstrate elevated cancer 
incidence associated with hypnotics
A 2008 paper59 listed three prior epidemiologic studies report-
ing associations of hypnotics with cancer deaths19,70,71. Analysis 
of CPSII data found that the elevation in deaths associated with 
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hypnotics was comparable to that associated with cigarettes71, 
though not entirely due to cancer. Mallon, Broman, and Hetta found 
a much higher cancer adjusted hazard ratio for habitual sleeping 
pill use of 5.3 (95% C.I. 1.8–15.4) than for smoking among males; 
none of the specific causes of death were individually significant 
among females70. A similar result was shown in a later paper for 
males, but the simple significant mortality elevation of regular hyp-
notic use among females was lost after multivariate adjustment in 
the second study32. More recently, a number of new studies have 
appeared reporting that hypnotic usage is related to cancer incidence 
and mortality. Hartz and Ross found a significant association of 
hypnotic use with melanoma and close-to-significant associa-
tions for lung and breast cancers72. Kao et al. found a remarkable 
6.24 (4.13–9.43, 95% CI) hazard ratio for cancer incidence 
among those using at least 300 mg of zolpidem per year with-
out other-benzodiazepine consumption (this would correspond to 
slightly more than one 5 mg dose per week)73. In this Taiwanese 
national study, smoking and body mass index (BMI) were not 
controlled, but the overall cancer hazard ratios for zolpidem users 
were almost identical among men and women, despite an almost 
11-fold greater prevalence of smoking among adult men com-
pared to Taiwanese women at the time74. BMI was not control-
led, but at that time in Taiwan, although being overweight was 
more common among women, obesity was more common among 
men75. However, hepatocellular carcinoma was not associated with 
zolpidem use in a case-control study76. In a complementary 
study of benzodiazepines in Taiwan, benzodiazepines were 
associated with a 1.19 (1.08–1.32 95% CI) cancer incidence 
hazard ratio, with over twice the benzodiazepine-associated haz-
ard among men as among  women77. Similarly, a brief analysis 
of the national data from Taiwan found a significant cancer 
adjusted odds ratio for two of three benzodiazepine hypnotics78.
In the Geisinger Health study using electronic medical records, 
Kripke et al. found a hazard ratio for cancer incidence of 1.35 
(1.18–1.55 95% CI) associated with use of >132 hypnotic doses per 
year, with specific hazard ratios of 1.28 (1.03–1.59) for high-dose 
zolpidem and 1.99 (1.57–2.52) for high-dose temazepam26. There 
was a significant dose-response. This study was carefully control-
led for age, gender, smoking, BMI, and by matching comorbidities 
among cases and controls. Jiao et al. found no excess of colorec-
tal cancer among those reporting sleeping pill usage <3 times per 
week versus ≥3 times per week in the Women’s Health Initiative 
data set79, a result consistent with the Hartz and Ross report on 
the same data set72, but since the contrast of frequencies of usage 
was weak and the type and quantity of hypnotic consumption were 
not determined objectively, the negative observation was not very 
persuasive. We would not expect hypnotics to promote all cancers 
equally. Indeed, selective specificity among cancer types would 
be anticipated if the mechanisms are causal. Pottegard et al. and 
Sivertsen et al. found small but significant associations of hypnotic 
usage with cancer, especially lung cancer80,81, but since they had not 
controlled for cigarette smoking, both groups thought their result 
might have arisen from confounding, albeit confounding was not 
conclusively demonstrated82. That investigators failed to control 
for important confounders is not proof that confounding explains 
the significant hazard. Several U.S. and European groups80,81 and 
also Kao et al.73 found high hazard ratios for lung and esophageal 
tumors, and the two San Diego studies had carefully control-
led for smoking26,71. We had proposed that effects of hypnotics 
on weakening the gastro-esophageal sphincter and permitting 
more gastro-esophageal regurgitation83 might account for the high 
cancer-specific rates of esophageal and lung tumors26. A new 
meta-analysis of epidemiological case-control and cohort studies 
found an overall cancer hazard ratio of 1.29 (1.08-1.53, 95% CI)84. 
This meta-analysis found that zolpidem had a higher hazard 
ratio than benzodiazepines and that particularly high hazard 
ratios were found for esophagus and lung cancers, among other 
cancer sites with statistical significance. These multiple stud-
ies finding hypnotics associated with human lung cancer were 
consistent with concerns of FDA scientists about lung cancers 
found in animal studies of zopiclone. The lung cancer specificity 
supports causality.
There was one pair of studies that was neither clearly confirma-
tory nor negative. A large-scale survey screening many drugs 
with a questionable scheme for reusing controls for multiple 
tests and incorporating a questionable 2-year drug-to-cancer lag 
remarked no significant association of cancer with temazepam 
or zolpidem but did find significant associations with oxazepam 
and perhaps lorazepam, using P<0.01 and relative risk >1.50 as 
criteria85. In that study, it was not always possible to control for 
smoking, and control for other confounders was crude and not 
well-standardized. A similar study added a possible association for 
phenobarbital86.
In a formal meta-analysis of 22 prospective cohort studies with 
2,482,625 participants suffering 312,203 incident cancers, ben-
zodiazepine drug use (including agonists) was found associated 
with increased cancer risk “(RR:1.25: 95% CI, 1.15-1.36)”, 
showing dose-response and dose-duration relationships and 
specificity among cancer types87.
To summarize the cancer epidemiology, the available clastogenic-
ity data, animal data, randomized placebo-controlled clinical 
trials, and human epidemiology studies rather consistently, if not 
always conclusively, suggested that hypnotics likely cause human 
cancers and cancer deaths.
Hypnotics increase incidence of clinical depression
In combined clinical trials, participants randomized to hypnot-
ics suffered 2.1 times as many incident (new) depressions as 
those randomized to placebo (P<0.002)34. These were not exac-
erbations of pre-existing depressions. These were depressions 
caused by the hypnotics. There are other data demonstrating 
worsening of depression with a wider variety of popular ben-
zodiazepine and GABA agonists88. Treatment of insomnia by 
hypnotics causing comorbid depression stands in marked con-
trast to cognitive-behavioral treatment of insomnia, that has been 
shown to decrease comorbid depression89,90 and otherwise improve 
mental health91.
Some studies have appeared designed to show that a hypnotic 
reduced depression scores among patients given an antidepressant 
known to cause insomnia92,93. In the first of these studies, the benefit 
of the hypnotic for depression was not significant at week 4 after 
Page 8 of 25
F1000Research 2018, 5:918 Last updated: 13 NOV 2018
the investigators removed the rating scale items related to insom-
nia, whereas the week 8 benefit was nominally significant only at 
the P=0.04 level not correcting for multiple comparisons. In other 
words, using rigorous Bonferroni correction for multiple compari-
sons, the alleged benefit of hypnotic for depression symptoms was 
not significant. In a second study the authors more readily con-
ceded that the hypnotic had no significant benefit for depression. 
These studies failed to rebut the evidence that hypnotics cause new 
depressions.
Hypnotic use is associated with high rates of suicide36,71,94. 
Depression is the major cause of suicide. Panic attacks are another 
risk factor for suicide88. Short-acting benzodiazepine agonists 
such as triazolam and zolpidem may cause withdrawal anxiety 
and even panic attacks during the daytime95. Suicide has been 
recently described as the 8th or 10th leading cause of death in the 
United States96,97. Indeed, comprehensive toxicological studies 
have found intoxicating abusable substances (mainly sedative- 
hypnotics) in a majority of suicides, often combined with alcohol 
in 30–40%88. Suicides due to overdoses have increased dramati-
cally from 1999 to 2010 in the U.S.98, but there have been an even 
larger number of deaths of undetermined manner in which suicide 
through overdose must be suspected99. A very recent report esti-
mated that in 2013 there were 7,000 overdose deaths related to 
anxiety and sleep medications97, but this did not include all sui-
cides in which the most rigorous toxicology shows a sedative or 
anxiolytic often mixed with alcohol to be present88. The adjusted 
odds rate for suicide was 4.2 among hypnotic users as compared 
to nonusers in one study of elderly people, whereas the odds were 
not elevated among anti-depressant users (tending to exclude 
depression and other comorbidities as confounders100.) Prescription 
sleeping pill use was a stronger predictor of suicide attempts 
than insomnia symptoms in the National Comorbidity Survey 
Replication101. In a large study from Taiwan, the adjusted suicide 
hazard ratio for “needing sleeping pills” was 11.1, whereas the 
hazard ratio for those reporting sleeping only 0–4 hours adjusted 
for sleeping pill use was only 3.5, and none of the hazard ratios 
for insomnia symptoms exceeded 2.0102. Another national 
Taiwan study found increased suicides and attempts associated 
with zolpidem94. The findings indicate that the association 
of suicides with hypnotic use cannot be entirely attributed to 
confounders with reverse causality, since the association of hyp-
notic usage with depression is known to be largely caused by 
the hypnotics34. Since the genetic influences promoting insom-
nia and depression appear highly correlated103, the associations 
both of depression and insomnia with mortality may be mediated 
through hypnotic drug consumption.
Zolpidem specifically has been implicated as a causal agent in a 
number of suicides, some of which involved kinds of dissocia-
tive behavior often attributed to zolpidem or to combined use of 
zolpidem with other drugs or alcohol104. Impairments of cogni-
tion and judgment that may be caused by sleeping pills105 as well 
as hallucinations106, irrational behaviors98,107–109, and behavioral 
disinhibition88 may all contribute to suicides, violence, and 
accidents, even among people who are not severely depressed. 
However, preliminary results of a recent study listed at https://
clinicaltrials.gov/ct2/show/results/NCT01689909 suggested that 8 
weeks treatment with zolpidem 10 mg. may have reduced suicidal 
ideation among patients treated with an SSRI antidepressant.
An authoritative review documented overwhelming evidence of 
the association of hypnotics with suicide but discerned no evi-
dence of causality110. However, new evidence shows that major 
components of depression and suicide are linked to infections. 
Those with inflammation indicated by high C-reactive protein 
(CRP) had more depression and bipolar disorder and more than 
twice the suicide rate of those with low CRP111–113. A Mendelian 
randomization study proved that CRP has a causal role111, though 
elevated TNF-alpha, interleukins, and other parts of the immune 
system may also be factors114–116. Since it is known that hypnotics 
cause infections that cause inflammation, a causal pathway from 
hypnotics to depression and suicide has been demonstrated.
Automobile crashes, falls, and other accidents are 
associated with hypnotics
Accidents of all sorts are associated with use of benzodiazepines 
and benzodiazepine agonists such as zolpidem117–119. Hypnotic drugs 
impair next-day alertness, motor skills, reasoning, and overall per-
formance. Most hypnotics impair automobile driving, as indicated 
by on-the-road controlled performance testing120. This impairment 
in some instances exceeds the impairment produced by a blood 
alcohol concentration of 0.05%121. Drivers’ ability to predict their 
own impairment is poor122. The use of hypnotics and other sedatives 
is strongly associated with driver hospitalization123 and on-the-road 
driver-at-fault crashes124–129. In addition to accidents attributable to 
impaired coordination, impaired motor skills and loss of alertness, 
hypnotics may also lead to fatal crashes due to drug induced sui-
cidal thinking, impaired judgment, or recklessness on the part of 
intoxicated drivers96. Hypnotics are a factor in more than half of 
intoxication and dangerous driving deaths.
Some crashes result in deaths of passengers and other-vehicle 
occupants not themselves using hypnotics, but non-driver deaths 
are not attributed to the hypnotics on death certificates. One 
study found that use of benzodiazepines and “Z” hypnotics was 
increased among victims of homicide as well as among the 
homicide perpetrators130. Thus, both through bad driving and 
homicides, hypnotics result in deaths that have not been accounted 
directly as deaths from these hypnotic drugs.
It is well known that falls and accidental injuries are strongly 
associated with hypnotic usage, in particular hip fractures among 
aging patients131–141. Hip fracture is a sometimes-lethal injury. 
The preponderance of studies indicates a true association of the 
use of hypnotics and falls, that is thought to be due to the prop-
erties of benzodiazepine agonists in inhibiting psychomotor 
skills and in causing weakness, slowed reflexes, and impaired 
judgment, especially less than 8 hours after ingestion. After 
taking a hypnotic at bedtime, older people may get up during 
the night, e.g., to visit the bathroom, when the pharmacologic 
impairment from a hypnotic is near-maximum and is com-
bined with impairments from sleepiness and the low point in the 
biological rhythm of performance. An interesting new system-
atic review observed that the risk of hip fracture was higher with 
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short-term than long-term use of benzodiazepines and Z-drugs, 
suggesting that the risk may be greatest before adaptation 
and tolerance develop142.
A nursing-home study challenged these conclusions, arguing that 
it was insomnia, not hypnotics, that was associated with falls. This 
study did not appear to control for confounding sleep apnea, Alzhe-
imer’s disease, or cognitive-behavioral disorders143. It should be 
conceded that confounders are likely have some influence on risk 
ratios associating hypnotics with accidental injuries, but the scien-
tific consensus suggests that the association is nevertheless partly 
causal, based in part on controlled trials showing hypnotic impair-
ments of driving and other forms of psychomotor performance. A 
causal element is inferred by the majority of authorities.
Safe doses of hypnotics for target populations are 
unknown
Animal studies indicate that some individuals in an animal research 
sample may succumb to a lethal hypnotic-drug effect at doses as 
low as one-fifth that which is universally lethal41. Variations in 
susceptibility in a human population varying in age, gender, genet-
ics, and health status is likely to be greater than that in a sam-
ple of laboratory animals. The minimum lethal dose of hypnotic 
drugs in humans is unknown, that is, the dose that might produce 
fatal respiratory arrest in one person out of 1000 in a represent-
ative population or one in 10,000. So many billions of hypnotic 
doses are prescribed yearly in the U.S. that one death per 10,000 
doses would yield over 100,000 deaths per year. Moreover, there 
are no human dose-response data and very little animal data 
concerning what doses of hypnotics may be lethal in the pres-
ence of opiates, other sedatives, alcohol, aging, obesity, COPD, 
and other comorbidities. Yet most recognized hypnotic-related 
deaths are observed in the presence of such additional factors. 
More study is needed to establish safe doses of hypnotics 
(if any) when taken with other medications and in the presence 
of potential comorbidities. As for aging, the consensus of the 
American Geriatrics Society is that hypnotics are not safe for 
elderly patients in any dose144.
Contributory factors combined with hypnotics could 
cause covert deaths
There is a vast discrepancy between the hundreds of thousands 
of yearly hypnotic-associated deaths implied by the high epide-
miologic hazard ratios and the mere thousands of yearly death 
certificates in which a hypnotic is listed among the causes of 
death. Below are presented some of the possible explanations for 
this discrepancy.
Obesity and aging exacerbate hypnotic risks
Obesity and aging are perhaps the two most important risk 
factors for sleep apneas, that is, brief cessations of breath-
ing during sleep145. Sleep apneas occurs at least a few times per 
hour in the majority of adults over age 40 years and in a great 
majority of those over age 65145,146. If the duration of a sleep 
apnea before arousal becomes excessively prolonged, e.g., by a 
hypnotic, death could result. Thus, hypnotic-related hazard 
ratios are higher among obese patients (see Geisinger Health 
study supplement Tables 2 and 726.) Since there is no evidence 
that the huge increase in hypnotic hazards among obese patients 
can be attributed overdoses, it appears that obesity predisposes 
to covert hypnotic-related deaths, probably by prolonging 
apneas. It is plausible that among susceptible patients, combina-
tions of aging, obesity, sleep apnea, hypnotics, opiates, other 
sedatives, and alcohol could produce quiet respiratory cessations 
followed by cardiac cessation and death even without any 
ingested doses above common medical practice being taken.
Prescription and non-prescription opiate use increase 
hypnotic risks
The use of opiates has become increasingly common in recent 
years147. Opiates are respiratory suppressants that (like pento-
barbital) in overdose can produce respiratory arrest and cardiac 
arrest. Among patients taking both benzodiazepines and opiates, a 
remarkable 75% were found to have sleep apnea, and causality 
was suggested by significant dose-response correlations both for 
the opiates and for the benzodiazepines148. In some patients, this 
combination of benzodiazepine and opiate causes hypoxemia 
(low oxygen)149. Our sleep clinic has recorded polysomnographic 
data from patients who suffered profound almost continuous apnea 
with severe hypoxemia due to combinations of hypnotics and 
opiates. Recall that it is understood on a molecular level how 
benzodiazepine agonists and opiates combine to suppress firing of 
respiratory neurons that are necessary to breathe. Patients receiv-
ing a combination of benzodiazepines and opiates have increased 
mortality10,150,151. The combination of opiates and benzodiazepines 
has caused a growing overdose problem in emergency rooms147. 
Moreover, the most serious overdose problems are seen when 
opiates and benzodiazepines are combined with alcohol in older 
patients, reflecting combined effects of opiate, benzodiazepine, 
alcohol, and aging10,15.
It may be relevant that close to 70% of hospice patients were 
taking an opiate and an anxiolytic or hypnotic in the last week 
of life152. This is not evidence by itself whether this combina-
tion influences the survival of hospice patients, nor is the author 
commenting on the ethics of combining such drugs in a genuine 
hospice situation. However, most patients given hypnotics and 
opiates combined have not consented to hospice management.
Quiet deaths from hypnotics with contributory factors go 
undetected by medical examiners and unrecorded
In combined-sedative deaths, the individual drug concentrations 
present in blood may appear within customary therapeutic ranges. 
Even if a patient is undergoing cardio-respiratory monitoring at 
the time when respiratory cessation followed by cardiac cessation 
occurs, there is usually no way of determining whether the fatal res-
piratory cessation was due to hypnotic drugs in combination with 
various contributory factors. Especially when death occurs quietly 
at night (for example, death of an elderly obese patient known to 
have various comorbidities,) there usually is no autopsy. Physicians 
signing the death certificates may be tempted to list a cardiac event 
or a stroke or some long-standing comorbidity as the cause of death 
without recognizing when hypnotic-induced respiratory suppres-
sion was the precipitant.
The press described a highly-distinguished example of how cause-
of-death data may be unreliable after U.S. Supreme Court Justice 
Scalia died unexpectedly at night. According to numerous news 
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reports and sheriff’s documents, Justice Scalia’s appearance was 
that of a person who had peacefully stopped breathing at night. 
There was no sign of agitation due to cardiac pain, nor had Justice 
Scalia complained of cardiac symptoms before going to bed. Justice 
Scalia might have been taking hypnotics and opiates for the jet lag 
and pain he was known to be suffering when he arrived at a hunting 
lodge that routinely gives each guest a free bottle of wine. Without 
ever viewing the deceased or his bedroom, much less determining 
what hypnotics, opiates for pain, and alcohol Justice Scalia might 
have consumed, a local official was guided by Justice Scalia’s phy-
sician (thousands of miles away) to declare heart attack as the cause 
of death. Without an autopsy, we will never know if this death was 
precipitated by hypnotics or opiates and alcohol or if there was a 
heart attack. Even if a physician suspects that a hypnotic had a role, 
the physician has little motivation to suggest the hypnotic as a cause 
of death when it would be hard to prove and may reflect negatively 
on whatever physician prescribed that hypnotic.
Along the same lines, when hypnotics cause infection, cancer, 
depression, falls or other accidents, or murder, hypnotics are rarely 
listed among the causes of death. These patterns along with quiet 
respiratory deaths may explain why epidemiology shows much 
higher risks of death associated with hypnotics than the death 
certificates document. Nevertheless, even the numbers documented 
in death certificates are too high to be acceptable.
Commonly-prescribed hypnotics are mainly used 
inappropriately
Zolpidem, reportedly the most commonly-prescribed hypnotic 
in the U.S., with an estimated 40 million outpatient prescriptions 
in 2013153, ranked first for emergency department visits among 
psychotropic drugs according to CDC data153,154. According to 
the Agency for Healthcare Research and Quality (AHRQ) data, 
68% of zolpidem patients were sustained users (three or more 
prescriptions), and of those 22% were also sustained users of 
opioids153. Note that recent CDC guidelines recommend against 
use of benzodiazepine agonists with opiates155. Although the FDA 
now recommends dosing women with only 5 mg or 6.25 mg of 
zolpidem, at least to begin with, only 5% of women and 10% of 
elderly were prescribed these low doses in 2012153. Apparently, 
there was little change in dosing for women and elderly after the 
FDA recommended the low doses in 2013153,156. Moreover, 23% of 
patients with sustained use took another drug targeting the same 
receptors. A high percentage were depressed, as indicated by 
34% of sustained zolpidem users also receiving antidepressants153. 
Similarly, a 1999–2010 compilation of NHANES data found that 
48% of those taking an insomnia medication were ≥60 years of 
age157. Moreover, over half of those who took a pill for insomnia 
in the past month were alcohol users (most moderate or heavy 
users), 56% took other sedatives, and 25% used opioids. In the 
NHANES data, only a minority of the sedatives taken for sleep 
were insomnia drugs, but most of the remainder were other 
benzodiazepines. Recall also that the American Geriatrics 
Society recommended avoidance of any use of hypnotics or 
benzodiazepines for elderly patients144, though about half of 
those receiving hypnotics have been elderly. Analyses of recent 
U.S. national data indicated that 77.4% of zolpidem prescription 
recipients had ≥2 safety contraindications158.
There is the further problem of hypnotic misuse in addition to 
the issues that the great majority of hypnotic prescriptions lack 
the indication of diagnosed insomnia, or have been prescribed 
despite contraindications, or have been prescribed in excessive 
dosages or for excessive durations. According the CBHSQ Report 
of the U.S. Substance Abuse and Mental Health Services Admin-
istration, misuse included taking the drug without a personal 
prescription, or in greater amounts or longer than instructed, or use 
in any other way a doctor did not direct159. The National Survey 
on Drug Use and Health estimated that in 2015, over 1.0 million 
U.S. adults misused prescription sedatives for sleep, and over 
1.2 million misused prescription tranquilizers to help with 
sleep159. A recent French study found that an indicator of “doctor 
shopping” to obtain zolpidem exceeded doctor shopping to obtain 
oxycodone and most other opiates160. Combining the evidence 
of lack of indication, excessive contraindications, and misuse, it 
appears that fewer than 10% consuming zolpidem were prescribed 
the drug in accord with the consensus approved circumstances. 
Hypnotics may cause death from overdoses of inappropriate 
drug-combination prescribing as well as other contributory 
factors, not only from a lethal dosage of the hypnotic considered 
by itself. 
Hypnotics cause withdrawal insomnia, anxiety, panic, 
and epilepsy
It has been well known since they came into use over a century 
ago that hypnotics and similar sedatives are addicting drugs, fre-
quently eliciting tolerance, physical dependence, and withdrawal 
reactions161. Most of the benzodiazepine agonist hypnotics and even 
suvorexant are controlled like addicting drugs by the U.S. Drug 
Enforcement Agency (DEA). Withdrawal from benzodiazepine 
agonists can cause insomnia, anxiety, agitation, confusion, and 
panic and even more severe somatic symptoms such as seizures 
and death in extreme cases35,95,155,162. In addition, some of the short-
acting sedatives such as triazolam and zolpidem may sometimes 
cause anxiety or agitation during the day following administration 
before the previous bedtime. Dr. Kripke has treated two patients 
taking triazolam who developed daytime panic attacks that remit-
ted upon triazolam withdrawal and recurred upon re-challenge. 
There is also evidence that prolonged use of hypnotics may lead to 
lasting insomnia, as a consequence causing patients who withdrew 
from hypnotics to sleep worse than patients who had been rand-
omized in parallel clinical trials to placeboes35. How long this with-
drawal insomnia might persist has never been adequately defined.
In another example of sedative withdrawal leading to hyperexcit-
ability, there is a report that benzodiazepine use and withdrawal 
may result in lasting increased epilepsy163.
Relationship of hypnotics to insomnia, long sleep, 
and short sleep
A pioneering large epidemiological study that the American Cancer 
Society conducted over 50 years ago observed an increased risk 
of death following hypnotic use. The Cancer Prevention Study I 
(CPSI) obtained questionnaires in 1958 from over 1,000,000 
participants and reliably ascertained their death or survival over 
6 years164. The data showed that both long and short sleep predicted 
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elevated mortality (with 7 hours associated with minimal mortality 
for each age group). This study (often replicated) raised scientific 
doubt whether there is medical value to increasing reported sleep 
duration of an adult beyond 7 hours, though it also demonstrated 
that many adults reporting more than 7 hours of sleep were tak-
ing sleeping pills. Sleep durations below the population median 
are partly attributable to inherited traits, so whether there would 
be any health benefit in sedating people with short sleep dura-
tions to sleep longer remains to be demonstrated. A small objec-
tive study of sleep duration recorded by wrist activity suggested 
increased mortality above 390 minutes of actual sleep (which is 
greater than the current median sleep of American adults studied 
with similar technology165.) In the CPSI data, self-reported insom-
nia had little or no additional mortality effect beyond hours of sleep, 
although insomnia was moderately associated with short sleep. 
In contrast, reported sleeping pill use was associated with about 
50% increased mortality after controlling for age, gender, reported 
sleep duration, and reported insomnia166. This was statistically a 
highly significant result in a million participants, but uncertainty 
about what participants meant by taking “sleeping pills” “Often” 
in terms of drug type and frequency demanded more study. The 
American Cancer Society performed a second Cancer Preven-
tion Study (CPSII) with participants completing over 1.1 million 
questionnaires in the fall of 1982. CPSII used more explicit 
questions about sleep duration, insomnia, and “prescription sleep-
ing pills.” After controlling simultaneously for 32 covariates 
and confounders such as insomnia and sleep duration in Cox 
Proportional Hazards models, results again showed that use of 
hypnotics was associated with elevated mortality not attribut-
able to major confounders such as cigarette smoking. Indeed, 
the mortality risk associated with taking “prescription sleeping 
pills” was surprisingly comparable to that associated with 
smoking a pack of cigarettes a day71.
More recent meta-analyses have indicated that the mortal-
ity risk associated with short sleep is minimal compared to that 
associated with long sleep167,168. Several recent studies have rep-
licated the CPSI and CPSII estimates that insomnia has little or 
no association with mortality after control for confounders169,170, 
but not all studies agree. Although a hypothesis that short 
sleep causes obesity has received recent popularity, some 
fostered by investigators affiliated with hypnotics manufac-
turers, no controlled trials indicating that hypnotics reduce 
obesity have been located. Epidemiologic data imply that 
hypnotic usage is more strongly associated with obesity than 
short sleep itself (see Lawman et al., supplement figure B)171. 
In summary, there is no scientific rationale that health would be 
improved by giving hypnotics for short sleep.
Benefits of hypnotics: minimal
Popular prescribed hypnotics fail objectively to increase 
sleep significantly even at high doses: new guidelines 
discourage hypnotic use
In an authoritative National Institutes of Health (NIH)-spon-
sored meta-analysis of controlled trials including unpublished 
trials172, Buscemi and colleagues found that although non-ben-
zodiazepine zolpidem-like drugs [“Z-drugs”] shortened sleep 
onset latency by an average of 12 minutes (9–17 min, 95% CI), 
according to objective polysomnograms, these hypnotics increased 
total nightly sleep time by only 11 minutes (-1 to 23 min, 95% 
CI, NS). That is, these “Z” drugs produced no substantial 
statistically-reliable increase in total sleep, even at doses higher 
than currently recommended. Most of the meta-analyzed 
studies of zolpidem used doses of 10 mg or more (as high as 
30 mg)172, and most of the studies of zopiclone used 7.5 mg 
doses or more (containing more eszopiclone than any dose 
approved in the U.S.) The FDA-approved recommended initial 
zolpidem dosage for most patients is now 5 mg (6.25 mg for the 
sustained-release form173.) Zolpidem and zolpidem-like drugs 
constitute the bulk of the current U.S. hypnotics market. Based 
on all available clinical studies, these lower doses would 
objectively increase sleep by trivial amounts if at all153. 
Indeed, the primary zolpidem manufacturer advised the FDA 
that the 5–6.25 mg dosages were generally ineffective44. The 
newly-recommended 1-mg dosage of eszopiclone is simi-
larly ineffective174,175 and even 3 mg. was ineffective in a small 
study176. Patients typically report more increase in sleep than is 
measured objectively, but even this self-reported “improvement” 
at above-recommended doses (which is not supported by objec-
tive measurement) is a mere 32 minutes (26–38 minutes, 95% 
CI)172. The discrepancies between objective and patient-subjective 
data may be attributable to the amnesic properties of hypnot-
ics, erasing patients’ memories of how much time they are awake 
in bed. In conclusion, the FDA-recommended doses of the most 
popular benzodiazepine agonists are virtually ineffective for 
objectively increasing sleep. Older benzodiazepines are not 
much more effective.
A new Comparative Effectiveness Review sponsored by the U.S. 
AHRQ has recently examined the Management of Insomnia 
Disorder, largely referring to chronic insomnia177. As a prepub-
lication Peer Reviewer of this report, I was and still remain very 
critical of its limitation to mainly-subjective data that are known 
to give a rosier evaluation of hypnotic effects than objective 
evaluations, its focus on published reports that are known to be 
commonly biased towards reporting favorable drug results178,179, 
and the AHRQ report’s incomplete attention to adverse effects. 
Nevertheless, it was striking that the AHRQ study found that 
the strongest evidence for treatment efficacy was with the 
cognitive-behavioral treatment of insomnia. The evidence for 
short-term efficacy of zolpidem and eszopiclone in high doses 
was considered less sufficient, and evidence for efficacy of 
other hypnotics was judged to be almost entirely insufficient. 
Moreover, by its clinical trial selection criteria, this Review 
found essentially no evidence for efficacy of the very low 
doses of zolpidem and eszopiclone currently recommended by 
the FDA for most patients, because higher doses appeared 
unsafe to FDA. In short, the AHRQ study presented no reason 
why hypnotics are needed, since cognitive-behavioral treatment 
of insomnia is better. The AHRQ Review found evidence for 
increased adverse effects with hypnotics compared to placebo, 
including hypnotic adverse effects of concern (their selec-
tion of studies highlighted fractures and dementia)180. This 
means that patients randomly treated with hypnotics tended to 
develop more illness and symptoms, quite the opposite of pro-
moting health. The Review found mention of adverse effects 
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virtually absent for the cognitive-behavioral treatment studies177. 
Although the Comparative Effectiveness Review found insuf-
ficient studies to estimate the comparative effectiveness of 
hypnotics versus cognitive-behavioral treatments, when it reviewed 
potential harms, there was no contest. Moreover, controlled 
trials reviewed above prove that hypnotics cause comorbidi-
ties such as infection and depression and driving impairments, 
whereas cognitive-behavioral treatment has been found to 
decrease medical comorbidities such as depression89.
Whatever weak evidence for benefits of hypnotics there has 
been came mainly from carefully selected groups of patients 
with diagnosed insomnia and few if any comorbidities or con-
traindications, and who generally did not use opiates or other 
sedatives or excess alcohol181. There are no clinical trials data 
demonstrating benefit among patients with multiple comorbidi-
ties and contraindications while lacking diagnosed insomnia, but 
such vulnerable patients are the majority of patients receiving 
hypnotics.
Derived from the AHRQ report, A Practice Guideline from the 
American College of Physicians made a still more reserved inter-
pretation of hypnotics’ benefits and risks182. This report advised that 
cognitive-behavioral treatments should always be the initial treat-
ment for insomnia disorder, and if this therapy was unsuccessful, 
then short-term use of hypnotics would be questionable. This 
Practice Guideline found the benefits of even short-term hypnotic 
treatment to be small or trivial and the evidence persuasive for 
balancing harms. The Practice Guideline did not recommend long-
term use of hypnotics at all. Going beyond the AHRQ report, that 
had not systematically investigated the evidence for severe risks, 
the Practice Guideline listed depression as a definite risk and 
cancer and excess mortality as possible risks, listing the evidence 
for these harms in considerable detail in its supplement. One 
wonders if the Practice Guideline would have approved use of 
the particular hypnotics with the most evidence of risks under any 
circumstances, were the authors aware of the up-to-date severe 
risk evidence detailed here. The American Geriatric Society and 
American College of Physicians guidelines were apparently 
written by experts without substantial financial conflicts. The 
European Guideline of the European Sleep Research Society, 
with few co-authors reporting financial conflicts, stated that 
they largely agreed with American College of Physicians guide-
lines, specifically favoring CBT over hypnotic treatments, and 
disapproving any hypnotic treatment beyond 4 weeks161.
A new randomized trial of CBT for insomnia showed that 
whereas zolpidem 10 mg. taken during the first few weeks added 
somewhat to benefits of CBT, those continuing on zolpidem slept 
worse on follow-ups of 6 months, 1 year, and 2 years183. This is 
one of the first randomized trials with long-enough follow-up 
to show that in the long run, a hypnotic made sleep subjectively 
worse.
In contrast, the first author of the 2017 American Academy of Sleep 
Medicine (AASM) Guideline for Pharmacologic Treatment of 
Insomnia184 had previously announced an AASM public awareness 
of insomnia campaign to “partner with a consortium of industry, 
from which we anticipate (and have already received) consider-
able financial support185.” The latest AASM Guideline did not dis-
close whether the AASM was receiving financial support from the 
hypnotics industry during its preparation, but certainly some of its 
authors were. Despite conflicting interests, the AASM acknowl-
edged that the evidence for efficacy of any hypnotic was “WEAK” 
or worse184. The AASM meta-analysis had demonstrably biased 
focus on sleep benefits of hypnotics, considering that they did 
not similarly assess risks. The AASM suggested use of the most 
popular hypnotics with which this review is concerned, even though 
conceding that they had insufficiently evaluated the less frequent 
but more serious harms on which this review has focused.
Hypnotics fail to improve next-day performance or general 
health
Based on manufacturers’ advertising, patients expect that a 
hypnotic will improve their function and performance the 
following day. The truth is just the opposite. In 1982, two sleep 
experts received support from a hypnotics’ manufacturer to 
survey the daytime performance literature about hypnotics and 
found, “Drug-related improvement in performance was not 
found, and, in comparing active drug to placebo, it is clear that 
all hypnotics, at some doses, produce decrements in perform-
ance the next day105.” Since 1982, the current author has been 
looking for objective evidence that hypnotics improve the 
performance of insomnia patients. Decades later, no evidence 
that GABA-agonist hypnotics improve objective daytime per-
formance in treating insomnia could be located. When there are 
proven significant effects, the effects are to make performance 
worse120,186,187. To reiterate, neither the AHRQ Comparative 
Effectiveness Review nor the AASM documented objective 
evidence of health or functional benefits from hypnotic drugs177. 
On average, most hypnotics make patients sleepier the next day, 
not more fully awake.
After 35 years, the author is still looking for any evidence of objec-
tive functional benefits. In a letter to Sleep Medicine, readers were 
asked to inform us if “any U.S.-licensed hypnotic ever objectively 
improved any aspect of insomnia patients’ daytime function or any 
aspect of general health188.” So far, nobody has informed me of any 
such evidence.
Hypnotic drugs are prescribed to patients without valid 
clinical indication
According to the U.S. National Ambulatory Medical Care Survey, 
insomnia is a stated reason for a patient’s visit in less than one quar-
ter of office visits where a hypnotic is prescribed4, but for most 
hypnotics, insomnia was the only approved indication. Moreo-
ver, no diagnosis of any sleep disorder at all is made on 35% of 
office visits when a hypnotic is prescribed, and of the 65% of such 
patients who are diagnosed with a sleep disorder (such as hyper-
somnia and most forms of sleep apnea), often a hypnotic would be 
contraindicated4. Other studies have likewise found that hypnot-
ics are commonly prescribed for patients who have no diagnosis 
or complaint of insomnia157,166,189,190. Hypnotics are routinely being 
prescribed without any apparent valid indication in as much as 
three quarters of the cases. Similarly, 46% of patients receiving 
polypharmacy of CNS drugs (such as benzodiazepines and 
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benzodiazepine agonists) had no pain, insomnia, or mental health 
diagnosis191. From the data reviewed it appears that in most 
cases, hypnotics are prescribed despite a specific contraindi-
cation such as aging. For example, in the 2015 Beers criteria of 
the American Geriatrics Society, the hypnotics of concern in 
this presentation are all listed as drugs to avoid144. It would be 
fanciful thinking to imagine that addicting hypnotics could be 
generally beneficial as usually prescribed: that is, without evidence 
of general health benefit, without indication, and despite specific 
contraindications.
Manufacturers misrepresent hypnotic benefits in direct-to-
consumer advertising
An instructive example is a 2006 advertisement representing that 
“[eszopiclone] provides a full night of sleep (7 to 8 hours).” An 
equivalent claim was made in a 2007 eszopiclone-hypnotic print 
advertisement titled “Sleep the night and seize the day…A bet-
ter tomorrow begins tonight.” In the scientific study cited by both 
advertisements as evidence192, the average sleep of patients receiv-
ing eszopiclone 2 mg was 382 minutes (6 hours, 22 min) and for 
3 mg, it was 412 minutes (6 hours, 52 min). The clinical results 
cited did not support the manufacturer’s claims to “a full 7 to 8 
hours of sleep,” even though the 2 mg and 3 mg doses then studied 
were greater than the currently-recommended starting doses.
As for the manufacturer’s advertised benefits of “seizing the day,” 
and a “better tomorrow,” the eszopiclone manufacturer’s study 
demonstrated no significant objective improvement in measured 
next-day daytime performance or accomplishment. Specifically, 
an objective morning performance test did not demonstrate signifi-
cantly better performance with eszopiclone than with placebo192.
It is not my intention to imply that misrepresentation in consumer 
advertising has come only from a single manufacturer. There have 
been many examples with other hypnotics.
Summary of benefits, risks, and alternatives
The evidence is clear: the most popular hypnotics offer little to 
no benefit to patients in recommended doses. The most recent 
American Academy of Sleep Medicine’s Clinical Guideline for 
Management of Chronic Insomnia193 stated that the primary goals 
of treatment of insomnia should be to increase sleep quantity and 
to enhance daytime function. To the contrary, popular hypnotics 
in recommended doses do not increase objective sleep substan-
tially (if at all,) and for many patients, hypnotics cause substantial 
objective next-day functional impairment. The specified hypnotics 
have no known objective benefits for any aspect of general health.
Contrasting with the dubious benefits, the popular benzodiazepine 
agonists in the U.S. are associated with increased mortality hazards, 
comparable to the hazards of barbiturates. Medical examiner data 
document that over 10,000 deaths every year are directly caused by 
and attributed to hypnotic drugs, and there is substantial evidence 
that hypnotics cause additional covert respiratory depression, sui-
cides, infection, cancer, accidents, and other disorders that lead to a 
far larger number of deaths as well as to non-fatal morbidities and 
suffering. The exact number of deaths caused by hypnotics cannot 
be estimated from medical examiner data alone147, because most 
of the deaths produced by hypnotics are covert or indirect due to 
hypnotic-induced or hypnotic-exacerbated morbidities.
The epidemiologic hypnotic mortality risk is almost comparable to 
that of cigarette smoking and many-fold greater than the risk to 
Americans of violent death.
•    Hypnotic drugs   300,000–500,000 U.S. deaths per year26
•    Cigarettes                       560,000 U.S. deaths per year194
•    Murders                          14,196 U.S. deaths in 2013
This presentation has focused primarily on zolpidem, temazepam, 
eszopiclone, zaleplon, triazolam, flurazepam, quazepam, and bar-
biturates used for sleep (such as pentobarbital, amobarbital, and 
secobarbital). These drugs were the focus because each had been 
shown epidemiologically to be associated with high mortality 
hazards26. This presentation has not focused on other drugs used 
as hypnotics, either because the epidemiologic and controlled- 
trials data have not been sufficient to assess their risks as hypnot-
ics or because these drugs are approved and may be effective for 
indications other than insomnia. Alternative hypnotics approved 
for treating insomnia in the U.S. include diphenhydramine, 
ramelteon, doxepin, and suvorexant. Moreover, other drugs 
commonly available for sleep include trazodone (off label) and 
melatonin (unregulated). The advantage of alternative drugs is that 
their risk-benefits ratios are less clearly known to be unfavorable, 
but the alternative drugs certainly have serious risks140.
Contrasted to hypnotics, the preferred treatment for insomnia is 
the cognitive-behavioral treatment of insomnia, which appears 
to be more effective in the long run, better for comorbidities, 
and safer177. Cognitive-behavioral therapy can be effectively pro-
vided through written materials, internet training programs, and 
brief group therapies. It has been argued that cognitive-behavioral 
treatment saves money, compared to hypnotics195.
Less known, circadian rhythm timing disorders often cause the 
biologic propensity for sleep to be either delayed (causing trou-
ble falling asleep and trouble waking in the morning) or too 
advanced (causing evening sleepiness and early awakening). It 
is unclear how often the circadian rhythm timing disorders have 
a more important role in insomnia than the cognitive-behavioral 
elements, but one estimate suggests that “eveningness” may be 
associated with trouble falling asleep in as much as one quarter of 
the adult population196. When circadian timing issues are impor-
tant, properly timed bright light treatment can be a safe, effec-
tive, and inexpensive non-drug treatment that also has benefits 
for comorbidities such as depression197. However, more clinical 
trials are needed to better define the applicability of bright light 
treatment for insomnia.
Grant information
The author(s) declared that no grants were involved in supporting 
this review.
Page 14 of 25
F1000Research 2018, 5:918 Last updated: 13 NOV 2018
Appendix A: Epidemiologic Studies of the Mortality 
Risks of Hypnotic Drugs
1)    Kronholm, E., Jousilahti, P., Laatikainen, T., Lallukka, T., 
Peltonen, M., Seppanen, J., and Virta, L. Trajectories in 
hypnotic use and approaching death: a register linked case- 
control study. Sleep Med. 2018; in press.
2)    Kabat, G. C., Xue, X., Kamensky, V., Zaslavsky, O., Stone, 
K. L., Johnson, K. C., Wassertheil-Smoller, S., Shadyab, 
A. H., Luo, J., Hale, L., Qi, L., Cauley, J. A., Brunner, R. 
L., Manson, J. E., and Rohan, T. E. The association of sleep 
duration and quality with all-cause and cause-specific mor-
tality in the Women’s Health Initiative. Sleep Med. 2018; 
50(10):48-54.
3)    Choi, J.-W., Lee, J., Jung, S. J., Shin, A., and Lee, Y. J. Use 
of sedative-hypnotics and mortality:  A population-based 
retrospective cohort study. J Clin Sleep Med. 2018;14(10), 
1669-1677.
4)    Mesrine, S., Gusto, G., Clavel-Chapelon, F., Boutron-Ruault, 
M. C., and Fournier, A. Use of benzodiazepines and cardio-
vascular mortality in a cohort of women aged over 50 years. 
Eur J Clin Pharmacol. 2018;74(11):1475-1484. 
5)    Sun, Y., Lin, C. C., Lu, C. J., Hsu, C. Y., and Kao, C. H. 
Association Between Zolpidem and Suicide: A Nationwide 
Population-Based Case-Control Study. Mayo Clin Proc. 
2016;91(3):308-315.
6)    Lan, T. Y., Zeng, Y. F., Tang, G. J., Kao, H. C., Chiu, H. J., 
Lan, T. H., and Ho, H. F. The use of hypnotics and mortality - A 
population-based retrospective cohort study. PLoS One. 10(12), 
e0145271. 2015.
7)    Palmaro A, Dupouy J, Lapeyre-Mestre M. Benzodiazepines and 
risk of death: Results from two large cohort studies in France 
and UK. Eur Neuropsychopharmacol 2015;25(10), 1566-1577.
8)    Chung, W. S., Lai, C. Y., Lin, C. L., and Kao, C. H. Adverse respi-
ratory events associated with hypnotics use in patients of chronic 
obstructive pulmonary disease: A population-based case-control 
Study. Medicine (Baltimore) 94(27), e1110. 2015.
9)    Kriegbaum, M., Hendriksen, C. Vass, M., Mortensen, E. L., 
Osler, M. Hypnotics and mortality—partial confounding by 
disease, substance abuse and socioeconomic factors? Pharma-
coepidemiol Drug Saf 2015;24(7):779-783.
10)    P inot J, Herr M, Robine JM, Aegerter P, Arvieu JJ, Ankri J. 
Does the Prescription of Anxiolytic and Hypnotic Drugs 
Increase Mortality in Older Adults? J Am Geriatr Soc 
2015;63(6):1263-5.
11)    Weisberg DF, Gordon KS, Barry DT, Becker WC, Crystal 
S, Edelman EJ, Gaither J, Gordon AJ, Goulet J, Kerns RD, 
Moore BA, Tate J, Justice AC, Fiellin DA. Long-term Prescrip-
tion of Opioids and/or Benzodiazepines and Mortality Among 
HIV-Infected and Uninfected Patients. J Acquir Immune Defic 
Syndr 2015;69(2):223-33.
12)    Nakafero G, Sanders RD, Nguyen-Van-Tam JS, Myles PR. 
Association between benzodiazepine use and exacerba-
tions and mortality in patients with asthma: a matched case- 
control and survival analysis using the United Kingdom 
Clinical Practice Research Datalink. Pharmacoepidemiol 
Drug Saf 2015;24(8):793-802.
13)     Neutel CI, Johansen HL. Association between hypnotics use 
and increased mortality: causation or confounding? Eur J 
Clin Pharmacol 2015;71(5):637-42.
14)    Frandsen R, Baandrup L, Kjellberg J, Ibsen R, Jennum P. 
Increased all-cause mortality with psychotropic medication 
in Parkinson’s disease and controls: a national register-based 
study. Parkinsonism Relat Disord 2014;20(11):1124-8.
15)    Weich S, Pearce HL, Croft P, Singh S, Crome I, Bashford J, 
Frisher M. Effect of anxiolytic and hypnotic drug prescrip-
tions on mortality hazards: retrospective cohort study. BMJ 
2014;348:g1996.
16)    Chen H-C, Su T-P, Chou P. A 9-year Follow-up Study of Sleep 
Patterns and Mortality in Community-Dwelling Older Adults 
in Taiwan. Sleep 2013;36(8):1187-98.
17)   Gunnell D, Chang SS, Tsai MK, Tsao CK, Wen CP. Sleep 
and suicide: an analysis of a cohort of 394,000 Taiwanese 
adults. Soc Psychiatry Psychiatr Epidemiol. 2013 Apr 2;48: 
1457-65.
18)    Jaussent I, Ancelin ML, Berr C, Peres K, Scali J, Besset A, 
Ritchie K, Dauvilliers Y. Hypnotics and mortality in an elderly 
general population: a 12-year prospective study. BMC Med 
2013;11(1):212.
19)    Obiora E, Hubbard R, Sanders RD, Myles PR. The impact of 
benzodiazepines on occurrence of pneumonia and mortality 
from pneumonia: a nested case-control and survival analysis 
in a population-based cohort. Thorax 2012;68(2):163-70.
20)    Hartz A, Ross JJ. Cohort study of the association of hypnotic 
use with mortality in postmenopausal women. BMJ Open 
2012;2:pii: e001413. doi: 10.1136/bmjopen-2012-001413.
21)     Kripke DF, Langer RD, Kline LE. Hypnotics’ association 
with mortality or cancer: a matched cohort study. BMJ Open 
2012;2(1):e000850.
22)    Gisev N, Hartikainen S, Chen TF, Korhonen M, Bell JS. Mor-
tality associated with benzodiazepines and benzodiazepine-
related drugs among community-dwelling older people in 
Finland: a population-based retrospective cohort study. Can J 
Psychiatry 2011;56(6):377-81.
23)    Rod NH, Vahtera J, Westerlund H, Kivimaki M, Zins M, 
Goldberg M, Lange T. Sleep Disturbances and Cause-Specific 
Page 15 of 25
F1000Research 2018, 5:918 Last updated: 13 NOV 2018
Mortality: Results From the GAZEL Cohort Study. Am J Epi-
demiol 2010;173(3):300-9.
24)    Belleville G. Mortality hazard associated with anxiolytic and 
hypnotic drug use in the national population health survey. 
Can J Psychiatry 2010;55(9):558-67.
25)    Mallon L, Broman JE, Hetta J. Is usage of hypnotics associ-
ated with mortality? Sleep Med 2009;10(3):279-86.
26)    Winkelmayer WC, Mehta J, Wang PS. Benzodiazepine use 
and mortality of incident dialysis patients in the United 
States. Kidney Int 2007;72(11):1388-93.
27)   Hublin C, Partinen M, Koskenvuo M, Kaprio J. Sleep and 
mortality: a population-based 22-year follow-up study. Sleep 
2007;30(10):1245-53.
28)    Hoffmann VP, Dossenbach M, West TM, Lowry AJ. Mortality 
in a cohort of outpatients with schizophrenia: 3-year outcomes 
from the Intercontinental Outpatient Health Outcomes Study 
(IC-SOHO). Biol Psychiatry 61(8S):163S-164S. Accessed 
2007.
29)    Hausken AM, Skurtveit S, Tverdal A. Use of anxiolytic or 
hypnotic drugs and total mortality in a general middle-
aged population. Pharmacoepidemiol Drug Saf 2007;16(8): 
913-8.
30)    Fukuhara S, Green J, Albert J, Mihara H, Pisoni R, 
Yamazaki S, Akiba T, Akizawa T, Asano Y, Saito A, Port F, 
Held P, Kurokawa K. Symptoms of depression, prescription 
of benzodiazepines, and the risk of death in hemodialysis 
patients in Japan. Kidney Int 2006;70(10):1866-72.
31)    Lack LC, Prior K, Luszcz M. 708. Does insomnia kill the 
elderly? Sleep 29[Abstract Supplement], A240. Accessed 
2006.
32)    Phillips B, Mannino DM. Does insomnia kill? Sleep 
2005;28(8):965-71.
33)    Ahmad R, Bath PA. Identification of risk factors for 15-year 
mortality among community-dwelling older people using Cox 
regression and a genetic algorithm. J Gerontol A Biol Sci Med 
Sci 2005;60A:1052-8.
34)    Mallon L, Broman J-E, Hetta J. Sleep complaints predict 
coronary artery disease mortality in males: a 12-year follow-
up study of a middle-aged Swedish population. J Int Med 
2002;251:207-16.
35)    Hedner J, Caidahl K, Sjoland H, Karlsson T, Herlitz J. Sleep 
habits and their association with mortality during 5-year 
follow-up after coronary artery bypass surgery. Acta Cardiol 
2002;57(5): 341-8.
36)    Kripke DF, Garfinkel L, Wingard DL, Klauber MR, Marler 
MR. Mortality associated with sleep duration and insomnia. 
Arch Gen Psychiatry 2002;59(2):131-6.
37)    Kripke DF, Klauber MR, Wingard DL, Fell RL, Assmus JD, 
Garfinkel L. Mortality hazard associated with prescription 
hypnotics. Biol Psychiatry 1998;43(9):687-93.
38)    Merlo J, Ostergren PO, Mansson NO, Hanson BS, 
Ranstam J, Blennow G, Isacsson SO, Melander A. Mortality in 
elderly men with low psychosocial coping resources using 
anxiolytic-hypnotic drugs. Scand J Public Health 
2000;28(4):294-7.
39)    Sundquist J, Ekedahl A, Johansson S-E. Sales of tranquilliz-
ers, hypnotics/sedatives and antidepressants and their relation-
ship with underprivileged area score and mortality and suicide 
rates. Eur J Clin Pharmacol 1996;51:105-9.
40)    Hays JC, Blazer DG, Foley DJ. Risk of napping: excessive 
daytime sleepiness and mortality in an older community popu-
lation. J Am Geriatr Soc 1996;44:693-8.
41)    Merlo J, Hedblad B, Ogren M, Ranstam J, Ostergren PO, 
Ekedahl A, Hanson BS, Isacsson SO, Liedholm H, Melander 
A. Increased risk of ischaemic heart disease mortality in eld-
erly men using anxiolytics-hypnotics and analgesics. Eur J 
Clin Pharmacol 1996;49:261-5.
42)    Brabbins CJ, Dewey ME, Copeland RM, Davidson IA, 
McWilliam C, Saunders P, Sharma VK, Sullivan C. Insom-
nia in the elderly: Prevalence, gender differences and 
relationships with morbidity and mortality. Int J Ger Psych 
1993;8:473-80.
43)    Thorogood M, Cowen P, Mann J, Murphy M, Vessey M. Fatal 
myocardial infarction and use of psychotropic drugs in young 
women. Lancet 1992;340:1067-8.
44)    Isacson D, Carsjo K, Bergman U, Blackburn JL. Long-
term use of benzodiazepines in a Swedish community: an 
eight-year follow-up. J Clin Epidemiol 1992 Apr;45(4): 
429-36.
45)   Rumble R, Morgan K. Hypnotics, sleep, and mortality in eld-
erly people. J Am Geriatr Soc 1992;40:787-91.
46)   Kripke DF, Simons RN, Garfinkel L, Hammond EC. Short and 
long sleep and sleeping pills: Is increased mortality associ-
ated? Arch Gen Psychiatry 1979;36(1):103-16.
Page 16 of 25
F1000Research 2018, 5:918 Last updated: 13 NOV 2018
References
1. Rudd RA, Aleshire N, Zibbell JE, et al.: Increases in Drug and Opioid Overdose 
Deaths--United States, 2000–2014. MMWR Morb Mortal Wkly Rep. 2016;  
64(50–51): 1378–82.  
PubMed Abstract | Publisher Full Text 
2. Ahman FB, Rossen LM, Spencer MR, et al.: Provisional drug overdose death 
counts. National Center for Health Statistics. Vital Statistics Rapid Release. 2018. 
Reference Source
3. Rockett IR, Lilly CL, Jia H, et al.: Self-injury Mortality in the United States in the 
Early 21st Century: A Comparison With Proximally Ranked Diseases. JAMA 
Psychiatry. 2016; 73(10): 1072–81.  
PubMed Abstract | Publisher Full Text | Free Full Text 
4. Ford ES, Wheaton AG, Cunningham TJ, et al.: Trends in Outpatient Visits for 
Insomnia, Sleep Apnea, and Prescriptions for Sleep Medications among US 
Adults: Findings from the National Ambulatory Medical Care Survey  
1999–2010. Sleep. 2014; 37(8): 1283–93.  
PubMed Abstract | Publisher Full Text | Free Full Text 
5. Crow D: Ambien defence: the real side effects of sleeping pills. Financial Times. 
Sect. US. 2018. 
Reference Source
6. Jalal H, Buchanich JM, Roberts MS, et al.: Changing dynamics of the drug 
overdose epidemic in the United States from 1979 through 2016. Science. 2018; 
361(6408): pii: eaau1184.  
PubMed Abstract | Publisher Full Text 
7. Doctor JN, Nguyen A, Lev R, et al.: Opioid prescribing decreases after learning 
of a patient’s fatal overdose. Science. 2018; 361(6402): 588–90.  
PubMed Abstract | Publisher Full Text 
8. Jones JD, Mogali S, Comer SD: Polydrug abuse: a review of opioid and 
benzodiazepine combination use. Drug Alcohol Depend. 2012; 125(1–2): 8–18. 
PubMed Abstract | Publisher Full Text | Free Full Text 
9. Larochelle MR, Zhang F, Ross-Degnan D, et al.: Trends in opioid prescribing and 
co-prescribing of sedative hypnotics for acute and chronic musculoskeletal 
pain: 2001–2010. Pharmacoepidemiol Drug Saf. 2015; 24(8): 885–92.  
PubMed Abstract | Publisher Full Text 
10. Liang Y, Goros MW, Turner BJ: Drug Overdose: Differing Risk Models for 
Women and Men among Opioid Users with Non-Cancer Pain. Pain Med. 2016; 
17(12): 2268–79.  
PubMed Abstract | Publisher Full Text 
11. Turner BJ, Liang Y: Drug Overdose in a Retrospective Cohort with Non-Cancer 
Pain Treated with Opioids, Antidepressants, and/or Sedative-Hypnotics: 
Interactions with Mental Health Disorders. J Gen Intern Med. 2015; 30(8): 1081–96. 
PubMed Abstract | Publisher Full Text | Free Full Text 
12. Dowell D, Arias E, Kochanek K, et al.: Contribution of Opioid-Involved Poisoning 
to the Change in Life Expectancy in the United States, 2000-2015. JAMA. 2017; 
318(11): 1065–7.  
PubMed Abstract | Publisher Full Text | Free Full Text 
13. Kolata G, Cohen S: Drug overdoses propel rise in mortality rates of young 
whites. International NY Times. 2016.  
Reference Source
14. Case A, Deaton A: Rising morbidity and mortality in midlife among white 
non-Hispanic Americans in the 21st century. Proc Natl Acad Sci U S A. 2015; 
112(49): 15078–83.  
PubMed Abstract | Publisher Full Text | Free Full Text 
15. Substance Abuse and Mental Health Services Administration CfBHSaQ: The 
DAWN Report: Benzodiazepines in combination with opioid pain relievers or 
alcohol: Greater risk of more serious ED visit outcomes. Dawn. 2014; 192: 1–6. 
Reference Source
16. Curtin SC, Warner M, Hedegaard H: Increase in Suicide in the United States, 
1999–2014. Hyattsville, M.D., National Center for Health Statistics. NCHS Data 
Brief. 2016; (241): 1–8.  
PubMed Abstract 
17. Krueger AB: Where Have All the Workers Gone? An Inquiry into the Decline of 
the U.S. Labor Force Participation Rate. Brookings Papers on Economic Activity. 
2017; 2017: 1–87.  
Reference Source
18. Jennum P, Baandrup L, Iversen HK, et al.: Mortality and use of psychotropic 
medication in patients with stroke: a population-wide, register-based study. 
BMJ Open. 2016; 6(3): e010662.  
PubMed Abstract | Publisher Full Text | Free Full Text 
19. Merlo J, Hedblad B, Ogren M, et al.: Increased risk of ischaemic heart disease 
mortality in elderly men using anxiolytics-hypnotics and analgesics. Results 
of the 10-year follow-up of the prospective population study “Men born in 
1914”, Malmo, Sweden. Eur J Clin Pharmacol. 1996; 49(4): 261–5.  
PubMed Abstract | Publisher Full Text 
20. Lan TY, Zeng YF, Tang GJ, et al.: The Use of Hypnotics and Mortality--A Population-
Based Retrospective Cohort Study. PLoS One. 2015; 10(12): e0145271.  
PubMed Abstract | Publisher Full Text | Free Full Text 
21. Patorno E, Glynn RJ, Levin R, et al.: Benzodiazepines and risk of all cause 
mortality in adults: cohort study. BMJ. 2017; 358: j2941.  
PubMed Abstract | Publisher Full Text | Free Full Text 
22. Kripke DF: Mortality Risk of Hypnotics: Strengths and Limits of Evidence. Drug 
Saf. 2016; 39(2): 93–107.  
PubMed Abstract | Publisher Full Text 
23. Ioannidis JP: Exposure-wide epidemiology: revisiting Bradford Hill. Stat Med. 
2016; 35(11): 1749–62.  
PubMed Abstract | Publisher Full Text 
24. Palmaro A, Dupouy J, Lapeyre-Mestre M: Benzodiazepines and risk of 
death: Results from two large cohort studies in France and UK. Eur 
Neuropsychopharmacol. 2015; 25(10): 1566–77.  
PubMed Abstract | Publisher Full Text 
25. Chung WS, Lai CY, Lin CL, et al.: Adverse Respiratory Events Associated 
With Hypnotics Use in Patients of Chronic Obstructive Pulmonary Disease: 
A Population-Based Case-Control Study. Medicine (Baltimore). 2015; 94(27): 
e1110.  
PubMed Abstract | Publisher Full Text | Free Full Text 
26. Kripke DF, Langer RD, Kline LE: Hypnotics’ association with mortality or cancer: 
a matched cohort study. BMJ Open. 2012; 2(1): e000850.  
PubMed Abstract | Publisher Full Text | Free Full Text 
27. Weich S, Pearce HL, Croft P, et al.: Effect of anxiolytic and hypnotic drug 
prescriptions on mortality hazards: retrospective cohort study. BMJ. 2014; 348: 
g1996.  
PubMed Abstract | Publisher Full Text | Free Full Text 
28. Neutel CI, Johansen HL: Association between hypnotics use and increased 
mortality: causation or confounding? Eur J Clin Pharmacol. 2015; 71(5): 637–42. 
PubMed Abstract | Publisher Full Text 
29. Kripke DF, Garfinkel L, Wingard DL, et al.: Mortality associated with sleep 
duration and insomnia. Arch Gen Psychiatry. 2002; 59(2): 131–6.  
PubMed Abstract | Publisher Full Text 
30. Geulayov G, Ferrey A, Casey D, et al.: Relative toxicity of benzodiazepines 
and hypnotics commonly used for self-poisoning: An epidemiological study 
of fatal toxicity and case fatality. J Psychopharmacol. 2018; 32(6): 654–662. 
PubMed Abstract | Publisher Full Text 
31. Chen HC, Su TP, Chou P: A nine-year follow-up study of sleep patterns and 
mortality in community-dwelling older adults in Taiwan. Sleep. 2013; 36(8): 
1187–98.  
PubMed Abstract | Publisher Full Text | Free Full Text 
32. Mallon L, Broman JE, Hetta J: Is usage of hypnotics associated with mortality? 
Sleep Med. 2009; 10(3): 279–86.  
PubMed Abstract | Publisher Full Text 
33. Belleville G: Mortality hazard associated with anxiolytic and hypnotic drug use 
in the national population health survey. Can J Psychiatry. 2010; 55(9): 558–67. 
PubMed Abstract | Publisher Full Text 
34. Kripke DF: Greater incidence of depression with hypnotic use than with 
placebo. BMC Psychiatry. 2007; 7: 42.  
PubMed Abstract | Publisher Full Text | Free Full Text 
35. Kripke DF: Hypnotics cause insomnia: evidence from clinical trials. Sleep Med. 
2014; 15(9): 1168–9.  
PubMed Abstract | Publisher Full Text 
36. Cooper JR: Sedative-Hypnotic Drugs: Risks and Benefits. Rockville, MD: U.S. 
Department of HEW, National Inst. on Drug Abuse; 1977.  
Reference Source
37. Kripke DF, Garfinkel L: Excess nocturnal deaths related to sleeping pill and 
tranquilliser use. Lancet. 1984; 1(8368): 99.  
PubMed Abstract | Publisher Full Text 
38. Leary S; Members of Panel: AVMA Guidelines for the Euthanasia of Animals: 
2013. Edition 2013.0.1. Schaumburg, IL: American Veterinary Medical Association; 
2013.  
Reference Source
39. Wikibooks contributors: Pentobarbital. Accessed 8-26-2015. Wikibooks, The Free 
Textbook Project. Wikibooks.  
Reference Source
40. Farkas RH, Katz R, Illoh K, et al.: Application Number 204569Orig1s000: Medical 
Review(s). Accessed 6-25-2013.  
Reference Source
41. Okamoto M, Rao SN, Aaronson LM, et al.: Ethanol drug interaction with 
chlordiazepoxide and pentobarbital. Alcohol Clin Exp Res. 1985; 9(6): 516–21. 
PubMed Abstract | Publisher Full Text 
42. Lalley PM: Opioidergic and dopaminergic modulation of respiration. Respir 
Physiol Neurobiol. 2008; 164(1–2): 160–7.  
PubMed Abstract | Publisher Full Text | Free Full Text 
43. Joya FL, Kripke DF, Loving RT, et al.: Meta-analyses of hypnotics and infections: 
eszopiclone, ramelteon, zaleplon, and zolpidem. J Clin Sleep Med. 2009; 5(4): 
377–83.  
PubMed Abstract | Free Full Text 
44. Farkas R, Center for Drug Evaluation and Research: Approval Package for: 
Application Number: 019908Orig1s032s034 021774Orig1s013s015. Accessed 
2013. Silver Spring, MD, FDA. 2013.  
Reference Source
45. Obiora E, Hubbard R, Sanders RD, et al.: The impact of benzodiazepines on 
occurrence of pneumonia and mortality from pneumonia: a nested case-
Page 17 of 25
F1000Research 2018, 5:918 Last updated: 13 NOV 2018
control and survival analysis in a population-based cohort. Thorax. 2013; 68(2): 
163–70.  
PubMed Abstract | Publisher Full Text 
46. Maeda T, Babazono A, Nishi T, et al.: Quantification of adverse effects of regular 
use of triazolam on clinical outcomes for older people with insomnia: a 
retrospective cohort study. Int J Geriatr Psychiatry. 2016; 31(2): 186–94.  
PubMed Abstract | Publisher Full Text 
47. Iqbal U, Syed-Abdul S, Nguyen PA, et al.: The impact of benzodiazepines on 
occurrence of pneumonia and mortality from pneumonia: a nested case-
control and survival analysis in a population-based cohort. Thorax. 2013; 68(6): 
591–2.  
PubMed Abstract | Publisher Full Text 
48. Huang CY, Chou FH, Huang YS, et al.: The association between zolpidem 
and infection in patients with sleep disturbance. J Psychiatr Res. 2014; 54(7): 
116–20.  
PubMed Abstract | Publisher Full Text 
49. Liao KF, Lin CL, Lai SW, et al.: Zolpidem Use Associated With Increased Risk of 
Pyogenic Liver Abscess: A Case-Control Study in Taiwan. Medicine (Baltimore). 
2015; 94(32): e1302.  
PubMed Abstract | Publisher Full Text | Free Full Text 
50. Lai SW, Lin CL, Liao KF: Increased relative risk of acute pancreatitis in 
zolpidem users. Psychopharmacology (Berl). 2015; 232(12): 2043–8.  
PubMed Abstract | Publisher Full Text 
51. Hsu FG, Sheu MJ, Lin CL, et al.: Use of Zolpidem and Risk of Acute 
Pyelonephritis in Women: A Population-Based Case-Control Study in Taiwan.  
J Clin Pharmacol. 2017; 57(3): 376–81.  
PubMed Abstract | Publisher Full Text 
52. Lai SW, Lai HC, Lin CL, et al.: Zopiclone use associated with increased risk of 
acute pancreatitis: a case-control study in Taiwan. Int J Clin Pract. 2015; 69(11): 
1275–80.  
PubMed Abstract | Publisher Full Text 
53. Nakafero G, Sanders RD, Nguyen-Van-Tam JS, et al.: Association between 
benzodiazepine use and exacerbations and mortality in patients with asthma: 
a matched case-control and survival analysis using the United Kingdom 
Clinical Practice Research Datalink. Pharmacoepidemiol Drug Saf. 2015; 24(8): 
793–802.  
PubMed Abstract | Publisher Full Text 
54. Pavon JM, Zhao Y, McConnell E, et al.: Identifying risk of readmission in 
hospitalized elderly adults through inpatient medication exposure. J Am 
Geriatr Soc. 2014; 62(6): 1116–21.  
PubMed Abstract | Publisher Full Text | Free Full Text 
55. Sanders RD, Godlee A, Fujimori T, et al.: Benzodiazepine augmented γ-amino-
butyric acid signaling increases mortality from pneumonia in mice. Crit Care 
Med. 2013; 41(7): 1627–36.  
PubMed Abstract | Publisher Full Text | Free Full Text 
56. Huemer HP, Lassnig C, Nowotny N, et al.: Diazepam leads to enhanced severity 
of orthopoxvirus infection and immune suppression. Vaccine. 2010; 28(38): 
6152–8.  
PubMed Abstract | Publisher Full Text 
57. Massoco C, Palermo-Neto J: Effects of midazolam on equine innate immune 
response: a flow cytometric study. Vet Immunol Immunopathol. 2003; 95(1–2): 
11–9.  
PubMed Abstract | Publisher Full Text 
58. Torres SR, Fröde TS, Nardi GM, et al.: Anti-inflammatory effects of peripheral 
benzodiazepine receptor ligands in two mouse models of inflammation. Eur J 
Pharmacol. 2000; 408(2): 199–211.  
PubMed Abstract | Publisher Full Text 
59. Kripke DF: Possibility that certain hypnotics might cause cancer in skin.  
J Sleep Res. 2008; 17(3): 245–50.  
PubMed Abstract | Publisher Full Text 
60. Roth T, Zammit GK, Scharf MB, et al.: Efficacy and safety of as-needed, post 
bedtime dosing with indiplon in insomnia patients with chronic difficulty 
maintaining sleep. Sleep. 2007; 30(12): 1731–8.  
PubMed Abstract | Free Full Text 
61. Scharf MB, Black J, Hull S, et al.: Long-term nightly treatment with indiplon in 
adults with primary insomnia: results of a double-blind, placebo-controlled, 
3-month study. Sleep. 2007; 30(6): 743–52.  
PubMed Abstract | Publisher Full Text | Free Full Text 
62. Weissinger J: NDA 19-908 Ambien Pharmacology Memos & Exclusivity 
Summary. 1991.  
Reference Source
63. Andreason PJ, Brugge K, Katz R; Center for Drug Evaluation and Research: 
Approval Package for: Application Number 21-476: Medical Review(s). 2004. 
Reference Source
64. Amerio A, Gálvez JF, Odone A, et al.: Carcinogenicity of psychotropic drugs: A 
systematic review of US Food and Drug Administration-required preclinical in 
vivo studies. Aust N Z J Psychiatry. 2015; 49(8): 686–96.  
PubMed Abstract | Publisher Full Text 
65. Roca R, McNeil DE, Center for Drug Evaluation and Research: Application 
Number 21-782: Medical Review(s). 2005; 1–315.  
Reference Source
66. Fitzgerald GG, Center for Drug Evaluation and Research: Application Number 
020859: Pharmacology Review(s). FDA, 1998.  
Reference Source
67. Wikipedia contributors: Clastogen. Wikipedia, Accessed 6-20-2014.  
Reference Source
68. Wasserman A, Mellon RD, Center for Drug Evaluation and Research: Application 
number 21-774: Pharmacology Reviews(s). FDA, 2005.  
Reference Source
69. Grivennikov SI, Greten FR, Karin M: Immunity, inflammation, and cancer. Cell. 
2010; 140(6): 883–99.  
PubMed Abstract | Publisher Full Text | Free Full Text 
70. Mallon L, Broman JE, Hetta J: Sleep complaints predict coronary artery disease 
mortality in males: a 12-year follow-up study of a middle-aged Swedish 
population. J Int Med. 2002; 251(3): 207–16.  
PubMed Abstract | Publisher Full Text 
71. Kripke DF, Klauber MR, Wingard DL, et al.: Mortality hazard associated with 
prescription hypnotics. Biol Psychiatry. 1998; 43(9): 687–93.  
PubMed Abstract | Publisher Full Text 
72. Hartz A, Ross JJ: Cohort study of the association of hypnotic use with 
mortality in postmenopausal women. BMJ Open. 2012; 2(5): pii:e001413. 
PubMed Abstract | Publisher Full Text | Free Full Text 
73. Kao CH, Sun LM, Liang JA, et al.: Relationship of zolpidem and cancer risk: a 
Taiwanese population-based cohort study. Mayo Clin Proc. 2012; 87(5): 430–6. 
PubMed Abstract | Publisher Full Text | Free Full Text 
74. Wen CP, Levy DT, Cheng TY, et al.: Smoking behaviour in Taiwan, 2001. Tob 
Control. 2005; 14 Suppl 1: i51–i55.  
PubMed Abstract | Publisher Full Text | Free Full Text 
75. Chu NF: Prevalence of obesity in Taiwan. Obes Rev. 2005; 6(4): 271–4.  
PubMed Abstract | Publisher Full Text 
76. Lai SW, Lin CL, Liao KF: Zolpidem Administration and Risk of Hepatocellular 
Carcinoma: A Case-Control Study in Taiwan. Front Pharmacol. 2017; 8: 767. 
PubMed Abstract | Publisher Full Text | Free Full Text 
77. Kao CH, Sun LM, Su KP, et al.: Benzodiazepine use possibly increases cancer 
risk: a population-based retrospective cohort study in Taiwan. J Clin Psychiatry. 
2012; 73(4): e555–e560.  
PubMed Abstract | Publisher Full Text 
78. Iqbal U, Jian WS, Huang CW, et al.: Do all hypnotic and sedatives have risk for 
cancer? Sleep Med. 2015; 20: 170.  
PubMed Abstract | Publisher Full Text 
79. Jiao L, Duan Z, Sangi-Haghpeykar H, et al.: Sleep duration and incidence of 
colorectal cancer in postmenopausal women. Br J Cancer. 2013; 108(1): 213–21. 
PubMed Abstract | Publisher Full Text | Free Full Text 
80. Pottegård A, Friis S, Andersen M, et al.: Use of benzodiazepines or 
benzodiazepine related drugs and the risk of cancer: a population-based case-
control study. Br J Clin Pharmacol. 2013; 75(5): 1356–64.  
PubMed Abstract | Publisher Full Text | Free Full Text 
81. Sivertsen B, Salo P, Pentti J, et al.: Use of sleep medications and risk of cancer: 
a matched case-control study. Sleep Med. 2015; 16(12): 1552–5.  
PubMed Abstract | Publisher Full Text 
82. Kripke DF, Langer RD: Evidence for harm, comment on ‘Use of benzodiazepines 
or benzodiazepine related drugs and the risk of cancer: a population-based 
case-control study’. Br J Clin Pharmacol. 2014; 78(1): 186–7.  
PubMed Abstract | Publisher Full Text | Free Full Text 
83. Gagliardi GS, Shah AP, Goldstein M, et al.: Effect of zolpidem on the sleep 
arousal response to nocturnal esophageal acid exposure. Clin Gastroenterol 
Hepatol. 2009; 7(9): 948–52.  
PubMed Abstract | Publisher Full Text 
84. Kim DH, Kim HB, Kim YH, et al.: Use of Hypnotics and Risk of Cancer: A Meta-
Analysis of Observational Studies. Korean J Fam Med. 2018; 39(4): 211–8. 
PubMed Abstract | Publisher Full Text | Free Full Text 
85. Friedman GD, Udaltsova N, Chan J, et al.: Screening pharmaceuticals for 
possible carcinogenic effects: initial positive results for drugs not previously 
screened. Cancer Causes Control. 2009; 20(10): 1821–35.  
PubMed Abstract | Publisher Full Text | Free Full Text 
86. Friedman GD, Jiang SF, Udaltsova N, et al.: Epidemiologic evaluation of 
pharmaceuticals with limited evidence of carcinogenicity. Int J Cancer. 2009; 
125(9): 2173–8.  
PubMed Abstract | Publisher Full Text | Free Full Text 
87. Zhang T, Yang X, Zhou J, et al.: Benzodiazepine drug use and cancer risk: a 
dose-response meta analysis of prospective cohort studies. Oncotarget. 2017; 
8(60): 102381–91.  
PubMed Abstract | Publisher Full Text | Free Full Text 
88. Youssef NA, Rich CL: Does acute treatment with sedatives/hypnotics for 
anxiety in depressed patients affect suicide risk? A literature review. Ann Clin 
Psychiatry. 2008; 20(3): 157–69.  
PubMed Abstract | Publisher Full Text 
89. Wu JQ, Appleman ER, Salazar RD, et al.: Cognitive Behavioral Therapy for 
Insomnia Comorbid With Psychiatric and Medical Conditions: A Meta-analysis. 
JAMA Intern Med. 2015; 175(9): 1461–72.  
PubMed Abstract | Publisher Full Text 
90. Luik AI, Kyle SD, Espie CA: Digital Cognitive Behavioral Therapy (dCBT) for 
Insomnia: a State-of-the-Science Review. Curr Sleep Med Rep. 2017; 3(2): 
Page 18 of 25
F1000Research 2018, 5:918 Last updated: 13 NOV 2018
48–56.  
PubMed Abstract | Publisher Full Text | Free Full Text 
91. Freeman D, Sheaves B, Goodwin GM, et al.: The effects of improving sleep on 
mental health (OASIS): a randomised controlled trial with mediation analysis. 
Lancet Psychiatry. 2017; 4(10): 749–758.  
PubMed Abstract | Publisher Full Text | Free Full Text 
92. Fava M, McCall WV, Krystal A, et al.: Eszopiclone co-administered with 
fluoxetine in patients with insomnia coexisting with major depressive 
disorder. Biol Psychiatry. 2006; 59(11): 1052–60.  
PubMed Abstract | Publisher Full Text 
93. Fava M, Asnis GM, Shrivastava RK, et al.: Improved insomnia symptoms and 
sleep-related next-day functioning in patients with comorbid major depressive 
disorder and insomnia following concomitant zolpidem extended-release 12.5 
mg and escitalopram treatment: a randomized controlled trial. J Clin Psychiatry. 
2011; 72(7): 914–28.  
PubMed Abstract | Publisher Full Text 
94. Sun Y, Lin CC, Lu CJ, et al.: Association Between Zolpidem and Suicide: A 
Nationwide Population-Based Case-Control Study. Mayo Clin Proc. 2016; 91(3): 
308–15.  
PubMed Abstract | Publisher Full Text 
95. Tan TL, Bixler EO, Kales A, et al.: Early morning insomnia, daytime anxiety, and 
organic mental disorder associated with triazolam. J Fam Pract. 1985; 20(6): 
592–4.  
PubMed Abstract 
96. Rockett IR, Caine ED: Self-injury is the eighth leading cause of death in the 
United States: It is time to pay attention. JAMA Psychiatry. 2015; 72(11): 1069–70. 
PubMed Abstract | Publisher Full Text 
97. Levi J, Segal LM, Martin A: The Facts Hurt: A state-by-state injury prevention 
policy report. Washington, D.C.: Trust for America’s Health; 2015.  
Reference Source
98. Pressman MR: Sleep driving: sleepwalking variant or misuse of z-drugs? Sleep 
Med Rev. 2011; 15(5): 285–92.  
PubMed Abstract | Publisher Full Text 
99. Breiding MJ, Wiersema B: Variability of undetermined manner of death 
classification in the US. Inj Prev. 2006; 12 Suppl 2: ii49–ii54.  
PubMed Abstract | Publisher Full Text | Free Full Text 
100. Carlsten A, Waern M: Are sedatives and hypnotics associated with increased 
suicide risk of suicide in the elderly? BMC Geriatr. 2009; 9(1): 20.  
PubMed Abstract | Publisher Full Text | Free Full Text 
101. Brower KJ, McCammon RJ, Wojnar M, et al.: Prescription sleeping pills, 
insomnia, and suicidality in the National Comorbidity Survey Replication.  
J Clin Psychiatry. 2011; 72(4): 515–21.  
PubMed Abstract | Publisher Full Text 
102. Gunnell D, Chang SS, Tsai MK, et al.: Sleep and suicide: an analysis of a cohort 
of 394,000 Taiwanese adults. Soc Psychiatry Psychiatr Epidemiol. 2013; 48(9): 
1457–65.  
PubMed Abstract | Publisher Full Text 
103. Gregory AM, Rijsdijk FV, Eley TC, et al.: A Longitudinal Twin and Sibling Study 
of Associations between Insomnia and Depression Symptoms in Young 
Adults. Sleep. 2016; 39(11): 1985–92.  
PubMed Abstract | Publisher Full Text | Free Full Text 
104. Darke S, Deady M, Duflou J: Toxicology and characteristics of deaths involving 
zolpidem in New South Wales, Australia 2001–2010. J Forensic Sci. 2012; 57(5): 
1259–62.  
PubMed Abstract | Publisher Full Text 
105. Johnson LC, Chernik DA: Sedative-hypnotics and human performance. 
Psychopharmacology (Berl). 1982; 76(2): 101–13.  
PubMed Abstract | Publisher Full Text 
106. Drover D, Lemmens H, Naidu S, et al.: Pharmacokinetics, pharmacodynamics, 
and relative pharmacokinetic/pharmacodynamic profiles of zaleplon and 
zolpidem. Clin Ther. 2000; 22(12): 1443–61.  
PubMed Abstract | Publisher Full Text 
107. Poceta JS: Zolpidem ingestion, automatisms, and sleep driving: a clinical and 
legal case series. J Clin Sleep Med. 2011; 7(6): 632–8.  
PubMed Abstract | Publisher Full Text | Free Full Text 
108. Tsai JH, Yang P, Chen CC, et al.: Zolpidem-induced amnesia and 
somnambulism: rare occurrences? Eur Neuropsychopharmacol. 2009; 19(1): 
74–6.  
PubMed Abstract | Publisher Full Text 
109. Morgenthaler TI, Silber MH: Amnestic sleep-related eating disorder associated 
with zolpidem. Sleep Med. 2002; 3(4): 323–7.  
PubMed Abstract | Publisher Full Text 
110. McCall WV, Benca RM, Rosenquist PB, et al.: Hypnotic Medications and Suicide: 
Risk, Mechanisms, Mitigation, and the FDA. Am J Psychiatry. 2017; 174(1): 
18–25.  
PubMed Abstract | Publisher Full Text | Free Full Text 
111. Wium-Andersen MK, Orsted DD, Nordestgaard BG: Elevated C-reactive 
protein, depression, somatic diseases, and all-cause mortality: a mendelian 
randomization study. Biol Psychiatry. 2014; 76(3): 249–57.  
PubMed Abstract | Publisher Full Text 
112. Batty GD, Bell S, Stamatakis E, et al.: Association of Systemic Inflammation 
With Risk of Completed Suicide in the General Population. JAMA Psychiatry. 
2016; 73(9): 993–5.  
PubMed Abstract | Publisher Full Text 
113. Wium-Andersen MK, Ørsted DD, Nordestgaard BG: Elevated C-reactive protein 
and late-onset bipolar disorder in 78 809 individuals from the general 
population. Br J Psychiatry. 2016; 208(2): 138–45.  
PubMed Abstract | Publisher Full Text 
114. Barnes J, Mondelli V, Pariante CM: Genetic Contributions of Inflammation to 
Depression. Neuropsychopharmacol. 2017; 42(1): 81–98.  
PubMed Abstract | Publisher Full Text | Free Full Text 
115. Jansen R, Penninx BW, Madar V, et al.: Gene expression in major depressive 
disorder. Mol Psychiatry. 2016; 21(3): 339–47.  
PubMed Abstract | Publisher Full Text 
116. Ma K, Zhang H, Baloch Z: Pathogenetic and Therapeutic Applications of Tumor 
Necrosis Factor-α (TNF-α) in Major Depressive Disorder: A Systematic Review. 
Int J Mol Sci. 2016; 17(5): pii: E733.  
PubMed Abstract | Publisher Full Text | Free Full Text 
117. Oster G, Huse DM, Adams SF, et al.: Benzodiazepine tranquilizers and the risk 
of accidental injury. Am J Public Health. 1990; 80(12): 1467–70.  
PubMed Abstract | Publisher Full Text | Free Full Text 
118. Lai MM, Lin CC, Lin CC, et al.: Long-term use of zolpidem increases the risk 
of major injury: a population-based cohort study. Mayo Clin Proc. 2014; 89(5): 
589–94.  
PubMed Abstract | Publisher Full Text 
119. Chung SD, Lin CC, Wang LH, et al.: Zolpidem Use and the Risk of Injury: A 
Population-Based Follow-Up Study. PLoS One. 2013; 8(6): e67459.  
PubMed Abstract | Publisher Full Text | Free Full Text 
120. Verster JC, Veldhuijzen DS, Patat A, et al.: Hypnotics and driving safety: meta-
analyses of randomized controlled trials applying the on-the-road driving test. 
Curr Drug Saf. 2006; 1(1): 63–71.  
PubMed Abstract | Publisher Full Text | Free Full Text
121. Verster JC, Spence DW, Shahid A, et al.: Zopiclone as positive control in studies 
examining the residual effects of hypnotic drugs on driving ability. Curr Drug 
Saf. 2011; 6(4): 209–18.  
PubMed Abstract | Publisher Full Text | Free Full Text
122. Verster JC, Roth T: Drivers can poorly predict their own driving impairment: 
a comparison between measurements of subjective and objective driving 
quality. Psychopharmacology (Berl). 2012; 219(3): 775–81.  
PubMed Abstract | Publisher Full Text | Free Full Text 
123. Yang YH, Lai JN, Lee CH, et al.: Increased risk of hospitalization related to 
motor vehicle accidents among people taking zolpidem: a case-crossover 
study. J Epidemiol. 2011; 21(1): 37–43.  
PubMed Abstract | Publisher Full Text | Free Full Text 
124. Orriols L, Philip P, Moore N, et al.: Benzodiazepine-like hypnotics and the 
associated risk of road traffic accidents. Clin Pharmacol Ther. 2011; 89(4): 
595–601.  
PubMed Abstract | Publisher Full Text 
125. Philip P, Chaufton C, Orriols L, et al.: Complaints of Poor Sleep and Risk of 
Traffic Accidents: A Population-Based Case-Control Study. PLoS One. 2014; 
9(12): e114102.  
PubMed Abstract | Publisher Full Text | Free Full Text 
126. Hansen RN, Boudreau DM, Ebel BE, et al.: Sedative Hypnotic Medication Use 
and the Risk of Motor Vehicle Crash. Am J Public Health. 2015; 105(8): e64–e69. 
PubMed Abstract | Publisher Full Text | Free Full Text 
127. Hemmelgarn B, Suissa S, Huang A, et al.: Benzodiazepine use and the risk of 
motor vehicle crash in the elderly. JAMA. 1997; 278(1): 27–31.  
PubMed Abstract | Publisher Full Text 
128. Gustavsen I, Bramness JG, Skurtveit S, et al.: Road traffic accident risk related 
to prescriptions of the hypnotics zopiclone, zolpidem, flunitrazepam and 
nitrazepam. Sleep Med. 2008; 9(8): 818–22.  
PubMed Abstract | Publisher Full Text 
129. Nevriana A, Möller J, Laflamme L, et al.: New, Occasional, and Frequent Use of 
Zolpidem or Zopiclone (Alone and in Combination) and the Risk of Injurious 
Road Traffic Crashes in Older Adult Drivers: A Population-Based Case-Control 
and Case-Crossover Study. CNS Drugs. 2017; 31(8): 711–722.  
PubMed Abstract | Publisher Full Text | Free Full Text 
130. Hedlund J, Ahlner J, Kristiansson M, et al.: A population-based study on 
toxicological findings in Swedish homicide victims and offenders from 2007 to 
2009. Forensic Sci Int. 2014; 244: 25–9.  
PubMed Abstract | Publisher Full Text 
131. Tinetti ME, Speechley M, Ginter SF: Risk factors for falls among elderly persons 
living in the community. N Engl J Med. 1988; 319(26): 1701–7.  
PubMed Abstract | Publisher Full Text 
132. Wang PS, Bohn RL, Glynn RJ, et al.: Hazardous benzodiazepine regimens in the 
elderly: Effects of half-life, dosage, and duration on risk of hip fracture. Am J 
Psychiatry. 2001; 158(6): 892–8.  
PubMed Abstract | Publisher Full Text 
133. Wang PS, Bohn RL, Glynn RJ, et al.: Zolpidem use and hip fractures in older 
people. J Am Geriatr Soc. 2001; 49(12): 1685–90.  
PubMed Abstract | Publisher Full Text 
134. Cumming RG, Le Couteur DG: Benzodiazepines and risk of hip fractures in 
older people: a review of the evidence. CNS Drugs. 2003; 17(11): 825–37. 
PubMed Abstract | Publisher Full Text 
Page 19 of 25
F1000Research 2018, 5:918 Last updated: 13 NOV 2018
135. Kang DY, Park S, Rhee CW, et al.: Zolpidem use and risk of fracture in elderly 
insomnia patients. J Prev Med Public Health. 2012; 45(4): 219–26.  
PubMed Abstract | Publisher Full Text | Free Full Text 
136. Berry SD, Lee Y, Cai S, et al.: Nonbenzodiazepine Sleep Medication Use and 
Hip Fractures in Nursing Home Residents. JAMA Intern Med. 2013; 173(9): 
754–61.  
PubMed Abstract | Publisher Full Text | Free Full Text 
137. Kolla BP, Lovely JK, Mansukhani MP, et al.: Zolpidem is independently 
associated with increased risk of inpatient falls. J Hosp Med. 2013; 8(1): 1–6. 
PubMed Abstract | Publisher Full Text 
138. Diem SJ, Ewing SK, Stone KL, et al.: Use of non-benzodiazepine sedative 
hypnotics and risk of falls in older men. J Gerontol Geriatr Res. 2014; 3(3): 158. 
PubMed Abstract | Publisher Full Text | Free Full Text 
139. Park SM, Ryu J, Lee DR, et al.: Zolpidem use and risk of fractures: a systematic 
review and meta-analysis. Osteoporos Int. In press, 2016; 27(10): 2935–44. 
PubMed Abstract | Publisher Full Text 
140. Frisher M, Gibbons N, Bashford J, et al.: Melatonin, hypnotics and their 
association with fracture: a matched cohort study. Age Ageing. 2016; 45(6): 
801–6.  
PubMed Abstract | Publisher Full Text 
141. Tom SE, Wickwire EM, Park Y, et al.: Nonbenzodiazepine Sedative Hypnotics 
and Risk of Fall-Related Injury. Sleep. 2016; 39(5): 1009–14.  
PubMed Abstract | Publisher Full Text | Free Full Text 
142. Donnelly K, Bracchi R, Hewitt J, et al.: Benzodiazepines, Z-drugs and the risk of 
hip fracture: A systematic review and meta-analysis. PLoS One. 2017; 12(4): 
e0174730.  
PubMed Abstract | Publisher Full Text | Free Full Text 
143. Avidan AY, Fries BE, James ML, et al.: Insomnia and hypnotic use, recorded 
in the minimum data set, as predictors of falls and hip fractures in Michigan 
nursing homes. J Am Geriatr Soc. 2005; 53(6): 955–62.  
PubMed Abstract | Publisher Full Text 
144. By the American Geriatrics Society 2015 Beers Criteria Update Expert Panel: 
American Geriatrics Society 2015 Updated Beers Criteria for Potentially 
Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2015; 63(11): 
2227–46.  
PubMed Abstract | Publisher Full Text 
145. Kripke DF, Ancoli-Israel S, Klauber MR, et al.: Prevalence of sleep-disordered 
breathing in ages 40-64 years: A population-based survey. Sleep. 1997; 20(1): 
65–76.  
PubMed Abstract | Publisher Full Text | Free Full Text 
146. Ancoli-Israel S, Kripke DF, Klauber MR, et al.: Sleep-disordered breathing in 
community-dwelling elderly. Sleep. 1991; 14(6): 486–95.  
PubMed Abstract | Publisher Full Text | Free Full Text 
147. Jann M, Kennedy WK, Lopez G: Benzodiazepines: a major component in 
unintentional prescription drug overdoses with opioid analgesics. J Pharm 
Pract. 2014; 27(1): 5–16.  
PubMed Abstract | Publisher Full Text 
148. Webster LR, Choi Y, Desai H, et al.: Sleep-disordered breathing and chronic 
opioid therapy. Pain Med. 2008; 9(4): 425–32.  
PubMed Abstract | Publisher Full Text 
149. Mogri M, Desai H, Webster L, et al.: Hypoxemia in patients on chronic opiate 
therapy with and without sleep apnea. Sleep Breath. 2009; 13(1): 49–57. 
PubMed Abstract | Publisher Full Text 
150. Park TW, Saitz R, Ganoczy D, et al.: Benzodiazepine prescribing patterns and 
deaths from drug overdose among US veterans receiving opioid analgesics: 
case-cohort study. BMJ. 2015; 350: h2698.  
PubMed Abstract | Publisher Full Text | Free Full Text 
151. Weisberg DF, Gordon KS, Barry DT, et al.: Long-term Prescription of Opioids 
and/or Benzodiazepines and Mortality Among HIV-Infected and Uninfected 
Patients. J Acquir Immune Defic Syndr. 2015; 69(2): 223–33.  
PubMed Abstract | Publisher Full Text | Free Full Text 
152. Dwyer LL, Lau DT, Shega JW: Medications That Older Adults in Hospice Care in 
the United States Take, 2007. J Am Geriatr Soc. 2015; 63(11): 2282–9.  
PubMed Abstract | Publisher Full Text 
153. Moore TJ: ISMP Quarter Watch: Monitoring FDA MedWatch Reports. Accessed 
5-06-2015. Philadelphia, PA, ISMP. Quarter Watch.  
Reference Source
154. Hampton LM, Daubresse M, Chang HY, et al.: Emergency Department Visits 
by Adults for Psychiatric Medication Adverse Events. JAMA Psychiatry. 2014; 
71(9): 1006–14.  
PubMed Abstract | Publisher Full Text | Free Full Text 
155. Dowell D, Haegerich TM, Chou R: CDC Guideline for Prescribing Opioids for 
Chronic Pain--United States, 2016. JAMA. 2016; 315(15): 1624–45.  
PubMed Abstract | Publisher Full Text 
156. Harward JL, Clinard VB, Jiroutek MR, et al.: Impact of a US Food and Drug 
Administration Drug Safety Communication on Zolpidem Dosing: An Observational 
Retrospective Cohort. Prim Care Companion CNS Disord. 2015; 17(2).  
PubMed Abstract | Publisher Full Text | Free Full Text 
157. Bertisch SM, Herzig SJ, Winkelman JW, et al.: National use of prescription 
medications for insomnia: NHANES 1999–2010. Sleep. 2014; 37(2): 343–9. 
PubMed Abstract | Publisher Full Text | Free Full Text 
158. Moore TJ, Mattison DR: Assessment of Patterns of Potentially Unsafe Use of 
Zolpidem. JAMA Intern Med. 2018; 178(9): 1275–1277.  
PubMed Abstract | Publisher Full Text 
159. Lipari RN, Williams M, Van Horn SL: Why Do Adults Misuse Prescription Drugs? 
Rockville, MD Center for Behavioral Health Statistics and Quality, SAMHSA. The 
CBHSQ Report. 2017. 
PubMed Abstract | Free Full Text
160. Ponté C, Lepelley M, Boucherie Q, et al.: Doctor shopping of opioid analgesics 
relative to benzodiazepines: A pharmacoepidemiological study among 11.7 
million inhabitants in the French countries. Drug Alcohol Depend. 2018; 187: 
88–94.  
PubMed Abstract | Publisher Full Text 
161. Riemann D, Baglioni C, Bassetti C, et al.: European guideline for the diagnosis 
and treatment of insomnia. J Sleep Res. 2017; 26(6): 675–700.  
PubMed Abstract | Publisher Full Text 
162. Institute of Medicine (US) Committee on Halcion: An Assessment of Data Adequacy 
and Confidence: Halcion: An Independent Assessment of Safety and Efficacy 
Data. Washington, D.C.: National Academy Press; 1997.  
PubMed Abstract | Publisher Full Text 
163. Harnod T, Wang YC, Kao CH: Association Between Benzodiazepine Use and 
Epilepsy Occurrence: A Nationwide Population-Based Case-Control Study. 
Medicine (Baltimore). 2015; 94(37): e1571.  
PubMed Abstract | Publisher Full Text | Free Full Text 
164. Hammond EC: Some preliminary findings on physical complaints from a 
prospective study of 1,064,004 men and women. Am J Public Health Nations 
Health. 1964; 54(1): 11–23.  
PubMed Abstract | Publisher Full Text | Free Full Text 
165. Kripke DF, Langer RD, Elliott JA, et al.: Mortality related to actigraphic long and 
short sleep. Sleep Med. 2011; 12(1): 28–33.  
PubMed Abstract | Publisher Full Text | Free Full Text 
166. Kripke DF, Simons RN, Garfinkel L, et al.: Short and long sleep and sleeping 
pills. Is increased mortality associated? Arch Gen Psychiatry. 1979; 36(1): 
103–16.  
PubMed Abstract | Publisher Full Text 
167. da Silva AA, de Mello RG, Schaan CW, et al.: Sleep duration and mortality in 
the elderly: a systematic review with meta-analysis. BMJ Open. 2016; 6(2): 
e008119.  
PubMed Abstract | Publisher Full Text | Free Full Text 
168. Shen X, Wu Y, Zhang D: Nighttime sleep duration, 24-hour sleep duration 
and risk of all-cause mortality among adults: a meta-analysis of prospective 
cohort studies. Sci Rep. 2016; 6: 21480.  
PubMed Abstract | Publisher Full Text | Free Full Text 
169. Kabat GC, Xue X, Kamensky V, et al.: The association of sleep duration and 
quality with all-cause and cause-specific mortality in the Women’s Health 
Initiative. Sleep Med. 2018; 50(10): 48–54.  
PubMed Abstract | Publisher Full Text 
170. Choi JW, Lee J, Jung SJ, et al.: Use of Sedative-Hypnotics and Mortality: A 
Population-Based Retrospective Cohort Study. J Clin Sleep Med. 2018; 14(10): 
1669–77.  
PubMed Abstract | Publisher Full Text | Free Full Text 
171. Lawman HG, Fryar D, Gu Q, et al.: The role of prescription medications in the 
association of self-reported sleep duration and obesity in U.S. adults, 2007–
2012. Obesity (Silver Spring). 2016; 24(10): 2210–6.  
PubMed Abstract | Publisher Full Text 
172. Buscemi N, Vandermeer B, Friesen C, et al.: The efficacy and safety of drug 
treatments for chronic insomnia in adults: a meta-analysis of RCTs. J Gen 
Intern Med. 2007; 22(9): 1335–50.  
PubMed Abstract | Publisher Full Text | Free Full Text 
173. Farkas RH, Unger EF, Temple R: Zolpidem and driving impairment--identifying 
persons at risk. N Engl J Med. 2013; 369(8): 689–91.  
PubMed Abstract | Publisher Full Text 
174. Rosenberg R, Caron J, Roth T, et al.: An assessment of the efficacy and safety 
of eszopiclone in the treatment of transient insomnia in healthy adults. Sleep 
Med. 2005; 6(1): 15–22.  
PubMed Abstract | Publisher Full Text 
175. Scharf M, Erman M, Rosenberg R, et al.: A 2-week efficacy and safety study of 
eszopiclone in elderly patients with primary insomnia. Sleep. 2005; 28(6): 720–7.  
PubMed Abstract | Publisher Full Text
176. Buxton OM, Pavlova MK, O'Connor SP, et al.: Lack of change in glucose 
metabolism in eszopiclone-treated primary insomnia patients. Nat Sci Sleep. 
2017; 9: 187–98.  
PubMed Abstract | Publisher Full Text | Free Full Text 
177. Brasure M, MacDonald R, Fuchs E, et al.: Management of Insomnia Disorder 
[Internet]. AHRQ Publication No. 15(16)-EHC027-EF, Accessed 12-30-2015. 
Rockville, MD, USA, Agency for Healthcare Research and Quality. Comparative 
Effectiveness Review. 1–288.  
PubMed Abstract 
178. Giles J: Drug trials: stacking the deck. Nature. 2006; 440(7082): 270–2.  
PubMed Abstract | Publisher Full Text 
179. Mattila T, Stoyanova V, Elferink A, et al.: Insomnia medication: do 
published studies reflect the complete picture of efficacy and safety? Eur 
Neuropsychopharmacol. 2011; 21(7): 500–7.  
PubMed Abstract | Publisher Full Text 
180. Chiu HY, Lin EY, Wei L, et al.: Hypnotics use but not insomnia increased the 
risk of dementia in traumatic brain injury patients. Eur Neuropsychopharmacol. 
2015; 25(12): 2271–7.  
PubMed Abstract | Publisher Full Text 
Page 20 of 25
F1000Research 2018, 5:918 Last updated: 13 NOV 2018
181. Roehrs T, Verster JC, Koshorek G, et al.: How representative are insomnia 
clinical trials? Sleep Med. 2018; 51: 118–23.  
PubMed Abstract | Publisher Full Text | Free Full Text 
182. Wilt TJ, MacDonald R, Brasure M, et al.: Pharmacologic Treatment of Insomnia 
Disorder: An Evidence Report for a Clinical Practice Guideline by the 
American College of Physicians. Ann Intern Med. 2016; 165(2): 103–12.  
PubMed Abstract | Publisher Full Text 
183. Beaulieu-Bonneau S, Ivers H, Guay B, et al.: Long-Term Maintenance of 
Therapeutic Gains Associated With Cognitive-Behavioral Therapy for Insomnia 
Delivered Alone or Combined With Zolpidem. Sleep. 2017; 40(3): zsx002. 
PubMed Abstract | Publisher Full Text | Free Full Text 
184. Sateia MJ, Buysse D, Krystal AD, et al.: Clinical Practice Guideline for the 
Pharmacologic Treatment of Chronic Insomnia in Adults: An American 
Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2017; 
13(2): 307–49.  
PubMed Abstract | Publisher Full Text | Free Full Text 
185. Sateia MJ: Increasing public awareness. J Clin Sleep Med. 2005; 1(2): 117–8. 
PubMed Abstract 
186. Boyle J, Groeger JA, Paska W, et al.: A method to assess the dissipation of 
the [corrected] residual effects of [corrected] hypnotics: eszopiclone versus 
zopiclone. J Clin Psychopharmacol. 2012; 32(5): 704–9.  
PubMed Abstract | Publisher Full Text 
187. Stranks EK, Crowe SF: The acute cognitive effects of zopiclone, zolpidem, 
zaleplon, and eszopiclone: a systematic review and meta-analysis. J Clin Exp 
Neuropsychol. 2014; 36(7): 691–700.  
PubMed Abstract | Publisher Full Text 
188. Kripke DF: I petitioned the FDA to restrict hypnotics: here is why. Sleep Med. in 
press, 2016; 23: 119–120.  
PubMed Abstract | Publisher Full Text 
189. Mellinger GD, Balter MB, Uhlenhuth EH: Insomnia and its treatment. Prevalence 
and correlates. Arch Gen Psychiatry. 1985; 42(3): 225–32.  
PubMed Abstract | Publisher Full Text 
190. Bjorvatn B, Meland E, Flo E, et al.: High prevalence of insomnia and hypnotic 
use in patients visiting their general practitioner. Fam Pract. 2017; 34(1):  
20–4.  
PubMed Abstract | Publisher Full Text 
191. Maust DT, Gerlach LB, Gibson A, et al.: Trends in Central Nervous System-
Active Polypharmacy Among Older Adults Seen in Outpatient Care in the 
United States. JAMA Intern Med.  2017; 177(4): 583–585.  
PubMed Abstract | Publisher Full Text | Free Full Text 
192. Zammit GK, McNabb LJ, Caron J, et al.: Efficacy and safety of eszopiclone 
across 6-weeks of treatment for primary insomnia. Curr Med Res Opin. 2004; 
20(12): 1979–91.  
PubMed Abstract | Publisher Full Text 
193. Schutte-Rodin S, Broch L, Buysse D, et al.: Clinical guideline for the evaluation 
and management of chronic insomnia in adults. J Clin Sleep Med. 2008; 4(5): 
487–504.  
PubMed Abstract | Free Full Text 
194. Carter BD, Abnet CC, Feskanich D, et al.: Smoking and mortality--beyond 
established causes. N Engl J Med. 2015; 372(7): 631–40.  
PubMed Abstract | Publisher Full Text 
195. Tannenbaum C, Diaby V, Singh D, et al.: Sedative-hypnotic medicines and 
falls in community-dwelling older adults: a cost-effectiveness (decision-tree) 
analysis from a US Medicare perspective. Drugs Aging. 2015; 32(4):  
305–14.  
PubMed Abstract | Publisher Full Text 
196. Kripke DF: When our body clocks run late: does it make us depressed? Ann 
Transl Med. In press. 2016; 49(9): 178.  
PubMed Abstract | Publisher Full Text | Free Full Text 
197. van Maanen A, Meijer AM, van der Heijden KB, et al.: The effects of light therapy 
on sleep problems: A systematic review and meta-analysis. Sleep Med Rev. 
2016; 29: 52–62.  
PubMed Abstract | Publisher Full Text 
Page 21 of 25
F1000Research 2018, 5:918 Last updated: 13 NOV 2018
 Open Peer Review
  Current Referee Status:
Version 3
 13 November 2018Referee Report
https://doi.org/10.5256/f1000research.18371.r21086
 Barbara A. Phillips
Division of Pulmonary, Critical Care, and Sleep Medicine, Good Samaritan Hospital, University of
Kentucky, Lexington, KY, USA
This update is on target, appropriate and approved by me.
 No competing interests were disclosed.Competing Interests:
Referee Expertise: epidemiology of sleep disorders
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
 13 November 2018Referee Report
https://doi.org/10.5256/f1000research.18371.r21087
 Jerome Siegel
Department of Psychiatry and Biobehavioral Sciences, Brain Research Institute, University of
California, Los Angeles, Los Angeles, CA, USA
No further comments.
 No competing interests were disclosed.Competing Interests:
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
Version 2
 17 March 2017Referee Report
https://doi.org/10.5256/f1000research.11965.r21113
 Jerome Siegel
Page 22 of 25
F1000Research 2018, 5:918 Last updated: 13 NOV 2018
  Jerome Siegel
Department of Psychiatry and Biobehavioral Sciences, Brain Research Institute, University of
California, Los Angeles, Los Angeles, CA, USA
I approve the revised manuscript.
 No competing interests were disclosed.Competing Interests:
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
Version 1
 27 May 2016Referee Report
https://doi.org/10.5256/f1000research.9393.r14033
 Barbara A. Phillips
Division of Pulmonary, Critical Care, and Sleep Medicine, Good Samaritan Hospital, University of
Kentucky, Lexington, KY, USA
This report is important and over due, and most likely would not be published in a journal that accepts
advertising from pharmaceutical companies. The author is careful NOT to confuse association with
causation. References are complete and up-to-date.
 No competing interests were disclosed.Competing Interests:
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
 23 May 2016Referee Report
https://doi.org/10.5256/f1000research.9393.r13914
 Jerome Siegel
Department of Psychiatry and Biobehavioral Sciences, Brain Research Institute, University of
California, Los Angeles, Los Angeles, CA, USA
This paper pulls together evidence from Dr. Kripke’s own work and subsequent work, which indicate that
the use of benzodiazepines and perhaps other sleeping pills is causing thousands, perhaps hundreds of
thousands of deaths annually in the United States. He reviews the complete lack of evidence for any
positive health effect of the use of these drugs.  This is especially striking because drug companies
sponsor a considerable amount of research on their sleeping pills and would undoubtedly publicize any
data indicating positive health or lifespan effects – but there do not appear to be any. Kripke also points
out the effectiveness of cognitive behavioral therapy for insomnia. This well studied treatment is less
expensive, without any known deleterious effects on lifespan or health and produces a long-lasting
reduction in insomnia. The effectiveness of cognitive behavioral therapy in the treatment of insomnia
contrasts with the miniscule (0-20 min) increase in sleep time produced by sleeping pills, followed by a
Page 23 of 25
F1000Research 2018, 5:918 Last updated: 13 NOV 2018
 1.  
2.  
3.  
contrasts with the miniscule (0-20 min) increase in sleep time produced by sleeping pills, followed by a
considerable withdrawal effect if the patient stops taking the pills.   
Minor suggestions include the following:
I would delete the discussion of Judge Scalia’s death. Although it gets one’s attention, without
knowing what Scalia was taking and without any documentation of the cause of death, it does more
harm than good to the impact of the paper.
 
On page 10, I would delete the paragraph on prescriptions without valid clinical indication. I guess
that in many cases the prescribing physician would just say he forgot to document the need. I do
not doubt that Dr. Kripke is bringing attention to an important issue, but it is not persuasively
presented, in contrast to the rest of his argument.
 
Small typo under “Obesity and aging exacerbate hypnotic risks:”  “can be attributed overdoses “
 No competing interests were disclosed.Competing Interests:
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
Author Response 30 May 2016
, University of California, San Diego, USADaniel F. Kripke
The kind reviews and useful contributions from Dr. Siegel and Dr. Phillips are much appreciated.
 
Regarding the paragraph about the death certificate of Justice Scalia, debate about his cause of
death and concern about the lack of autopsy received considerable press attention in major media
in the United States. The process by which a rural judge decided what cause of death to record on
the death certificate was uniquely well documented by the press. This illustrated how a death that
could have been due to an overdose might not be explored and the overdose possibility might not
be recorded.  Knowing what the patient’s primary doctor had or had not prescribed would not
resolve the issue of what drugs were or were not taken. This paragraph was intended to exemplify
how we may indeed lack adequate documentation of the real cause of death when the plausible
possibility of death caused by a hypnotic is not acknowledged on a death certificate.
 
Regarding hypnotic prescriptions without a recorded diagnosis of insomnia, indeed the prescribing
physician might just say that forgetting to document the insomnia was an oversight, but it is
implausible that oversight is the explanation for such a large percentage of total hypnotic
prescriptions. If lack of indication is usually an oversight, where is the proof? When I was a medical
student in the 1960’s, I was trained that a hypnotic drug should be part of preprinted routine
admission orders, and I have verified that routine admission orders for hypnotics are still preprinted
in distinguished academic training hospitals in 2016. If we are training young doctors to prescribe a
hypnotic without asking the patient whether that patient is experiencing trouble sleeping and
without weighing the benefits and risks for the individual, it is plausible that habit persists in primary
care. My impression is that prescribing doctors often do not ascertain that the patient has
diagnostic criteria for insomnia, and in many cases, physicians know that the patient has no trouble
sleeping. The physician might be trying to treat depression or to supplement opiates, but both uses
are contraindicated. The physician might be treating some condition further afield such as
hypertension or might be intentionally trying to achieve a placebo effect. There were studies
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 hypertension or might be intentionally trying to achieve a placebo effect. There were studies
documenting such practices several decades ago (references 126 and 136), but I know of no
adequate study of 21  century U.S. outpatient hypnotic prescribing intentions.  The manufacturers
of both zolpidem and suvorexant have informed the FDA that the currently-FDA-mandated
recommended doses are ineffective. It is tempting to infer that the FDA countenances the use of
ineffective hypnotic doses as placebo implements of the bedside manner, without evidence that
benefits outweigh risks of potentially addicting or lethal placeboes. 
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